Medicine and method for treating infectious diseases
A medicament using serial dilutions of antibodies against HLA-DRB1 and β2-MG, combined with other antibodies, addresses antibiotic resistance and viral inefficacy by enhancing antibiotic effectiveness and reducing dosage and side effects.
Patent Information
- Application Number
- JP2024125562
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-08-29
- Filing Date
- 2024-08-01
- Publication Date
- 2024-11-06
AI Technical Summary
The increasing prevalence of antibiotic-resistant bacteria and the limitations of current treatments for bacterial and viral infections, including side effects and inefficacy against certain pathogens, necessitate the development of new medicaments that enhance antibiotic efficacy and reduce resistance.
A medicament comprising multiple serial dilutions of antibodies against HLA-DRB1 and β2-MG, combined with other antibodies such as IFN-γ and CD4, is administered to increase antibiotic effectiveness against resistant bacteria and viruses, reducing the required dosage and minimizing side effects.
The medicament enhances the pharmacological effectiveness of antibiotics against resistant bacteria and viruses, reduces bacterial resistance, and decreases the necessary antibiotic dosage, while minimizing side effects and broadening the scope of treatment against mixed infections.
Smart Images

Figure 2024156824000011 
Figure 2024156824000012 
Figure 2024156824000013
Abstract
Description
[Technical field]
[0001] The present invention relates to the field of medicines, in particular to medicaments and methods for treating infectious diseases. In particular, the present invention relates to products for treating infectious diseases caused by bacteria, products for improving the therapeutic effect of antibiotics, including promoting their effect against resistant bacteria and reducing the effective dose of antibiotics, as well as methods for treating bacterial infections, reducing bacterial resistance to antibiotic therapy, reducing the effective dose of antibiotics, and enhancing the therapeutic effect of antibiotics against antibiotic-specific resistant bacteria. The present invention also relates to medicaments and methods for treating viral infections. [Background technology]
[0002] Infectious diseases can be classified as simple, i.e., caused by one agent, and mixed, i.e., caused by two or more agents. It is important to distinguish mixed infections from secondary infections (superinfections) that arise from a current illness. Reinfection is defined as the recurrence of disease caused by the same agent after complete recovery and is associated with a lack of immunity.
[0003] Bacterial infections are diseases caused by bacteria. They are characterized by the secretion of toxins by live and dead bacteria, which lead to inflammation, intoxication, and tissue damage. Diagnosis of bacterial infection requires the prescription of antibacterial drugs. Bacteria causing various diseases eventually show resistance to the antibiotics used for treatment. This is a natural adaptive process called antibacterial resistance. The emergence of many resistant bacteria increases incurable infections, leading to an increased risk of bacterial infections, higher medical costs associated with the treatment of bacterial infections, longer hospital stays, and higher mortality rates [Non-Patent Document 1].
[0004] In May 2015, the World Health Assembly endorsed a global action plan to tackle antimicrobial resistance, including antibiotic resistance. The goal of the global action plan is to ensure the treatment and prevention of infections with effective and safe medicines [http: / / www.who.int / mediacentre / factsheets / antibiotic-resistance / ru / ].
[0005] Acute upper respiratory tract infections (URI) are the most common group of diseases worldwide, including infections caused by influenza, parainfluenza, respiratory syncytial virus, rhinovirus, and adenovirus, as well as other catarrhal inflammations of the upper respiratory tract. Viral infections usually occur by self-introduction of the virus into the nasal or conjunctival mucosa after contact with an infected individual or contaminated surfaces. Another mode of infection is airborne infection, which occurs by inhalation of virus-containing aerosols or exposure of mucous membranes to infectious droplets when a person is in close contact with an infected individual. Lack of adequate treatment or ineffective treatment can lead to severe complications such as otitis media, sinusitis, tonsillitis, and disseminated intravascular coagulation.
[0006] An analysis of official statistical data from the World Health Organization (WHO) showed that at the beginning of the 21st century, infectious diseases accounted for a quarter of all deaths worldwide, while in developing countries, the mortality rate due to infectious diseases reached almost 50%. Infectious diseases remain one of the most important causes of death in the world population. The development of new treatment options for these diseases is a top priority for the medical and pharmaceutical industries.
[0007] Therefore, treatment of viral and bacterial infections, as well as methods to reduce antibiotic resistance and increase bacterial susceptibility to antibiotics, are currently important challenges in the medical community.
[0008] The prior art discloses drugs for treating infectious diseases, in particular antiviral drugs, such as arbidol, amixin, etc. [https: / / www.rlsnet.ru / tn_index_id_4196.htm, https: / / www.rlsnet.ru / tn_index_id_1526.htm]. This class of drugs can have side effects and lack effectiveness against certain viral diseases [Non-Patent Document 2].
[0009] The prior art also discloses drugs for treating infectious diseases, in particular medicinal products for the treatment of bacterial infections, such as amoxicillin, gentamicin, tetracycline, levomycin, etc. [https: / / www.rlsnet.ru / tn_index_id_222.htm / / https: / / www.rlsnet.ru / tn_index_id_876.htm / / https: / / www.rlsnet.ru / mnn_index_id_82.htm / / https: / / www.rlsnet.ru / tn_index_id_4699.htm]. Antibiotics have two major problems: the increase in the number of antibiotic-resistant microorganisms and the wide range of contraindications and side effects associated with their use [Non-Patent Document 3].
[0010] Thus, inappropriate and uncontrolled use of antibiotics can be very harmful to human health. Apart from adverse events such as allergies, toxic sequelae of the liver and kidney, cardiovascular, hematological, and nervous system disorders, antibiotic treatment can also lead to the development of antibiotic-resistant microorganisms. Therefore, comprehensive efforts aimed at reducing antibiotic resistance in microorganisms and promoting judicious use of antibiotics are now important.
[0011] Methods are known to combat bacterial drug resistance, which means the use of antibiotics in combination with bacterial enzyme inhibitors. For example, there is clavulanic acid (or clavulanate), a beta-lactamase inhibitor with a chemical structure similar to beta-lactam antibiotics. Like other beta-lactams, clavulanic acid can bind to penicillin-binding proteins (PBPs) of gram-positive and gram-negative bacteria and contribute to the dissolution of the bacterial wall. Furthermore, clavulanic acid has its own antibacterial action. On this basis, combination medicines have been prepared that contain aminopenicillins and one of the beta-lactamase inhibitors (amoxicillin / clavulanate). The disadvantage of this method is that the antagonistic range of the drug combination used is limited, i.e. it is only effective against bacteria with beta-lactamase-mediated resistance. Side effects of clavulanic acid are gastrointestinal disorders, cholestatic jaundice, liver dysfunction, hepatitis, Clostridium difficile infection, candidiasis, and allergies (erythema multiforme, angioedema, exfoliative dermatitis, allergic urticaria, and anaphylactic shock) [https: / / www.kakprosto.ru / kak-899440-klavulanovaya-kislota-deystvie-i-svoystva-#ixzz5eejsFIpF].
[0012] The prior art discloses a method for overcoming bacterial and fungal drug resistance by improving the effective approach to microbial drug resistance to antibacterial agents with various action mechanisms through the combined action of low concentrations of aniline dyes and antibacterial agents [Patent Document 1]. Note that aniline dyes are widely used in histology and have antibacterial effects, but some also exhibit carcinogenic effects.
[0013] The prior art also discloses pharmaceutical combinations of active antibacterial and proteolytic enzymes for external and topical application. The compositions include a base (e.g., lyzoamidase) and at least one target supplement (antibiotic, synthetic antibacterial (including agents that reduce microbial resistance, antifungal, anesthetic, or repair stimulant)). The present invention ensures an increase in the therapeutic activity of the pharmaceutical composition compared to known drugs, including against strains resistant to the individual components of the composition. It also improves the healing process, promotes faster wound cleansing, and shortens the time to recovery [Patent Document 2]. It should be noted that enzymes are sensitive to various environmental factors (pH, temperature, pressure, etc.), and exposure to external factors can lead to irreversible changes in the structure of the enzyme denaturing and subsequently losing its properties. For example, it is recommended that the lyzoamidase enzyme be stored in a dark and dry environment at ≦+10° C., which presents additional challenges in its manufacture, shipping, and storage, since its effectiveness can be reduced during any of these steps.
[0014] The prior art discloses medicines containing ultra-low doses of monoclonal and polyclonal, as well as activated forms of immune or natural antibodies against major histocompatibility complexes (HLA complexes) or HLA antigen complexes and their associated peptides [Patent Document 3]. The immunotropic drug obtained according to the present invention is a new drug characterized by immunotropic activity, no side effects, clean environment, and low cost. However, there is no data on the efficacy of this drug in the treatment of bacterial and / or viral infections.
[0015] The prior art discloses a combination drug for treating viral infections, which contains as active ingredients an activated-potentiated form of an antibody against human interferon gamma and an activated-potentiated form of an antibody against the CD4 receptor [Patent Document 4]. However, there is no data on the efficacy of this drug in treating bacterial or mixed infections.
[0016] Ergoferon is the closest analogue of the claimed drug [https: / / www.rlsnet.ru / tn_index_id_46844.htm]. The pharmacological activity of ergoferon includes antiviral and immunomodulatory effects, in addition, the drug is also used in the combined treatment of bacterial infections. Ergoferon contains the so-called activation-enhanced forms of antibodies against human interferon gamma (IFN-γ), activation-enhanced forms of antibodies against CD4 of T cells (CD4) and activation-enhanced forms of antibodies against histamine (His). Summary of the Invention
[0017] The aim of the present invention is to form new and effective drug combinations which show high antiviral, antibacterial and immunomodulatory activity and are also effective against bacteria resistant to one or more known antibacterial drugs (antibiotics) without causing toxic or mutagenic effects on the patient's organism. The present invention also aims to develop medicines which increase the pharmacological effectiveness of antibiotics, in particular their effectiveness against resistant bacteria, allowing the effective dose of antibiotics to be reduced.
[0018] In one embodiment, the medicament of the invention is a technical process resulting from multiple serial dilutions of stock materials, i.e., antibodies against HLA-DRB1 and antibodies against β2-MG. In another embodiment, the medicament of the invention is a technical process resulting from multiple serial dilutions of stock materials, i.e., a) HLA-DRB1, b) β2-MG, c) IFN-γ, and d) CD4. Both embodiments are useful for the treatment and prevention of bacterial infections caused by various types of pathogens.
[0019] One aspect of the present invention is a claimed medicine for treating bacterial infections which is a technical process resulting from multiple serial dilutions of a stock material, i.e., antibodies against the β1 domain of major histocompatibility complex class II molecules (HLA-DRB1) and antibodies against β2-microglobulin (β2-MG), promoting improved antibiotic efficacy, reduced bacterial resistance to antibiotic therapy, and reduced effective dose of antibiotics.
[0020] Another aspect of the present invention is a claimed pharmaceutical having antibacterial and antiviral activity for treating infectious diseases, which is a technical process resulting from multiple serial dilutions of stock substances: a) antibodies against β1 domain of major histocompatibility complex class II molecules (HLA-DRB1), b) antibodies against β2-microglobulin (β2-MG), c) antibodies against interferon gamma (IFN-γ), and d) antibodies against CD4.
[0021] The types of bacteria mentioned can be, for example, the following: spirochetes (e.g. Treponema, Borrelia, Leptospira); gram-negative aerobic and microaerophilic, motile, curved and spiral bacteria (e.g. Campylobacter, Helicobacter, Spirillum); gram-negative aerobic and microaerophilic rods and cocci (e.g. Achromobacter, Bordetella, Kingella, Neisseria); gram-negative facultative anaerobic rods (e.g. Sedecea, Escherichia, Klebsiella, Plesiomonas, Haemophilus, Streptobacillus (coli infections)); gram-negative anaerobic straight, curved and spiral bacteria (e.g. Anaerobiospirrilum, Bacteroids, Pollen, etc.); Phyllomonas); Gram-negative anaerobic cocci (e.g., Veillonella); Rickettsia and Chlamydia (e.g., Ehrlichia, Chlamydophila); Gram-positive cocci (e.g., Aerococcus, Staphylococcus, Streptococcus); Gram-positive endospore-forming bacilli and cocci (e.g., Bacillus, Clostridium); Regularly shaped Gram-positive non-spore-forming bacilli (e.g., Erysipelothrix, Listeria); Irregularly shaped Gram-positive non-spore-forming bacilli (e.g., Bifidobacterium, Corynebacterium, Rothia); Mycobacteria (e.g., Mycobacterium); Actinomycetes (e.g., Actinomadura, Nocardia, Streptomyces); Mycoplasmas (e.g., Mycoplasma, Ureaplasma), etc. [IV Smirnov. Pathogens of bacterial infections in humans. Clinical Microbiology and Antimicrobial Chemotherapy, No.2, Vol. 2, 2000, p.4-11].
[0022] The claimed medicine, which is a technical process resulting from multiple serial dilutions of stock materials of antibodies against HLA-DRB1 and β2-MG, respectively, is also effective against bacteria resistant to one or more antibiotics.
[0023] Bacterial infections that can be managed by the claimed medicines can be divided into classes based on both the type of pathogenic bacteria and its mode of infection.
[0024] Bacterial gastrointestinal / intestinal infections can be caused by Shigella, Staphylococcus, Vibrio cholerae, Salmonella typhi, or Salmonella (salmonellosis, typhoid, dysentery, bacterial food poisoning, campylobacteriosis, enteritis, escherichiosis, colitis, food poisoning, gastritis, ulcerative disease, botulism, etc.). The fecal-oral route is predominant for these infections.
[0025] Airborne bacterial infections of the respiratory tract can be caused by Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pertussis, Neisseria meningitidis, Chlamydia, Mycobacteria, Mycoplasma, etc. (e.g. sinusitis, rhinitis, acute tonsillitis, laryngitis, tracheitis, tonsillitis, epiglottitis, maxillary sinusitis, pneumonia, bronchitis, tuberculosis, etc.).
[0026] Bacterial infections of the urogenital system, such as bacterial vaginosis (gardnerellosis), chlamydia, cystitis, bacterial overgrowth, pyelonephritis, glomerulonephritis, urethritis, bacterial balanitis, prostatitis, bacterial cystitis, bacterial prostatitis, orchitis, etc.;
[0027] For example, bacterial infections of the skin and soft tissue caused by staphylococci and streptococci are transmitted by skin contact (erysipelas, impetigo, cellulitis, phlegmon, furunculosis, hidradenitis, etc.).
[0028] For example, blood infections caused by Rickettsia, Yersinia, and Coccobacillus have a route of infection (rabbit fever, plague, spotted fever, trench fever, etc.).
[0029] Infections of the lymphatic system, such as inflammation of the lymph glands and lymphangitis, can be caused by streptococci or staphylococci;
[0030] Infections of the nervous system, such as meningitis, encephalitis, myelitis, and other infections (caused by Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae b, Borrelia, Mycoplasma, Candida, etc.), are transmitted through the airway and lymphatic system;
[0031] Bone and joint infections can be caused by bacterial pathogens such as Lyme disease, Staphylococcus, Streptococcus, Mycobacteria, and Gonococcus, and can be transmitted via the bloodstream, through direct contact, e.g., through open wounds or surgical procedures, and through infection in nearby body structures (septic arthritis, osteomyelitis, Reiter's syndrome, etc.);
[0032] Ear infections (mastoid and sinus infections) can be caused by Streptococcus and Staphylococcus, Candida, Haemophilus influenzae, etc. Infection can occur through the Eustachian tube, from the ear canal, or by blood (otitis interna, sensorineural hearing loss, mastoiditis, etc.).
[0033] The pharmaceutical composition of the present invention is a combination of active ingredients for the treatment of bacterial infections, namely a combination of a drug representing a technical process obtained by multiple serial dilutions of stock materials of antibodies against HLA-DRB1 and antibodies against β2-MG, and a corresponding antibiotic, both of which are co-administered to the patient. The co-administration of the drug and the corresponding antibiotic can be carried out by simultaneous administration of the drugs as two independent products (as separate dosage forms) or consecutively with a required time interval (especially if these intervals allow the combination of the respective products to exert an improved effect). The method of selection is determined empirically and depends on the disease and the antibiotic used.
[0034] The claimed medicament together with a known antibiotic may also constitute either a fixed or non-fixed pharmaceutical combination used for the treatment of bacterial infections. The term "fixed combination" indicates that the active ingredients, i.e. the claimed medicament and the partner drug (antibiotic), are co-administered to the patient simultaneously as a single pharmaceutical dosage form or dose. The term "non-fixed combination" or "set of ingredients" indicates that the active ingredients, i.e. the claimed medicament and the partner drug (antibiotic), are co-administered to the patient simultaneously or sequentially as separate ingredients without a specific time interval (if such administration ensures effective levels of the two active ingredients in the body). The claimed combination of medicament and antibiotic may be administered simultaneously or sequentially for the treatment of bacterial infections, the antibiotic being administered in a known effective dose.
[0035] The claimed medicine (antibody against HLA-DRB1 and antibody against β2-MG) is used in an effective amount selected by experiment, but the antibiotics should be taken according to the package insert or a doctor's prescription. The antibiotics include antibiotics from the following groups, such as: beta-lactam antibiotics (penicillins (amoxicillin, methicillin, oxacillin, benzylpenicillin, etc.); cephalosporins (cephalexin, cefazolin, ceftriaxone, cefepime, etc.); carbapenems (meropenem, doripenem, biapenem, etc.); macrolides (ketolide, erythromycin, roxithromycin, clarithromycin, etc.); tetracyclines (tetracycline, oxytetracycline, doxycycline, methacycline, etc.); aminoglycosides (streptomycin, kanamycin, amikacin, gentamicin, etc.); chlorocyclines (tetracycline, oxytetracycline, doxycycline, methacycline, etc.); The antibiotics may be selected from mycetins; oxazolidinones; glycopeptides (such as thalgoside, daptomycin, vancomycin, etc.); lincosamides (dalacin C); fluoroquinolones (such as levofloxacin, gemifloxacin, sparfloxacin, etc.); antifungal antibiotics (such as nystatin, amphotericin B, etc.); antituberculous antibiotics (such as futibazide, methazide, salzide, etc.); antileprosy drugs (such as solusulfon, diuciphon, etc.); antitumor agents (such as doxorubicin, rubomycin, carminomycin, etc.); and other antibiotics (such as fosfomycin, fucidin, rifampicin, etc.). JPEG2024156824000001.jpg989
[0036] Effective dose (ED) or effective concentration (ЕС) is defined as the dose or concentration of a drug that elicits a biological response. The term "effective dose" is used in reference to in vivo measurements and the term "effective concentration" is used in reference to in vitro measurements.
[0037] The present invention is intended to improve the pharmacological activity of antibiotics, especially their action against resistant bacteria, through simultaneous or sequential administration of the corresponding antibiotic and the claimed medicine, which represents a technical process resulting from multiple serial dilutions of stock substances of each antibiotic against HLA-DRB1 and β2-MG. Thus, the co-administration of the claimed medicine with the antibiotic facilitates the reduction of the dosage of the antibiotic.
[0038] The medicament of the present invention is a technical process resulting from multiple serial dilutions of stock materials, i.e. a) HLA-DRB1, b) β2-MG, c) IFN-γ, and d) CD4, and can be used for the treatment of viral infections. The viral infections referred to may be caused by viruses of the order Herpesvirales, Adenoviridae, Papillomaviridae, Polyomaviridae; single-stranded DNA viruses (e.g. Circoviridae, Parvoviridae); viruses with replicable RNA (e.g. Reoviridae, Birnaviridae); positive-sense single-stranded RNA viruses (e.g. Nidovirales, Picornavirales, Tymovirales, Astroviridae, Caliciviridae, Flaviviridae, Togaviridae, Virugaviridae); negative-sense single-stranded RNA viruses (e.g. Bunyavirales, Mononegavirales, Arenaviridae, Ophioviridae, Orthomyxoviridae, Deltavirus); positive-sense single-stranded RNA viruses that replicate via a DNA intermediate (e.g. Retroviridae); double-stranded DNA viruses that replicate via a single-stranded RNA intermediate (e.g. Caulimoviridae, Hepadnaviridae). JPEG2024156824000002.jpg7148
[0039] Furthermore, the pharmaceutical of the present invention, which is a technical process resulting from multiple serial dilutions of stock material, i.e., a) HLA-DRB1, b) β2-MG, c) IFN-γ, and d) CD4, is effective against mixed infections resulting from simultaneous exposure to two or more different pathogens, both viruses and bacteria, and secondary infections (superinfections) occurring following infection with another pathogen.
[0040] The technical effect of the present invention is to broaden the scope of medicines with combined antiviral and antibacterial activity, and to form broad-spectrum antibacterial agents that are effective against bacteria that are resistant to one or more antibiotics and exhibit low toxicity or mutagenicity, thereby reducing the burden on the patient's body during antibacterial therapy. The claimed medicine enhances the pharmacological effectiveness of antibiotics, including their effectiveness against resistant bacteria, reduces their effective dose, and minimizes side effects during and after antibiotic treatment.
[0041] The technical products resulting from multiple serial dilutions of stock materials of antibodies against HLA-DRB1, β2-MG, IFN-γ and CD4 are aqueous or hydroalcoholic solutions of the antibodies (or a combination of these solutions) obtained by serial dilution (potentization) of the antibody matrix solution, each dilution being subjected to a succussion process.
[0042] In previous applications [Russian Patent No. 2205025C1 (December 26, 2001); Russian Patent No. 2500422C2 (August 6, 2010), etc.], the applicant has used the terms "activated form of antibody", "enhanced activated form of antibody", "ultra-high dilution", and "ultra-low dose of antibody" to describe technical processes resulting from multiple serial dilutions of antibody stock material. The Applicant also emphasizes that the terms "released active form" and "activated form of antibody", "enhanced activated form of antibody", "ultra-low dose of antibody", "ultra-high dilution" and "active dilution" can be used interchangeably [Epstein OI Released-activity (contemporary view on homeopathy and non-homeopathy). Moscow: RAMS Publishing House, 2017. 48 p. / / Epstein OI Ultralow doses (history of one study). Moscow: RAMS Publishing House, 2008. 336 p.].
[0043] In the present invention, antibody dilutions are from C2 onwards (i.e. 100 2 The term antibody-matrix solution is defined as any dilution of the antibody-matrix solution including 10-fold, 100-fold, and 1000-fold dilutions (starting from a matrix solution diluted 1:2x), as well as any combination thereof (e.g., C2+D34+M45, D20+C4, etc.) and any dilution ratio (e.g., 1:1:2, 2:3, etc.).
[0044] The claimed medicines are prepared using natural, monoclonal or mainly polyclonal antibodies as stock materials having antigen specificity against the corresponding antigens, i.e. HLA-DRB1, β2-MG, IFN-γ and CD4, which can be obtained according to known techniques and methods described in Myagkova MA, Morozova VS Immunochemical properties of natural antibodies to physiologically active compounds, Fundamental Research No. 11, 2014, p.1066-1070 and Immunological methods edited by G. Frimel, Мoscow, Meditsina, 1987, p.9-33; or for example in the document by Laffly E., Sodoyer R. Hum. Antibodies. Monoclonal and recombinant antibodies, 30 years after. - 2005 - Vol.14. - N 1-2. P.33-55.
[0045] Natural antibodies are defined as immunoglobulins secreted by the body in limited amounts in the absence of exogenous antigenic stimulation. Thus, these antibodies are also present in the circulation of healthy humans. Natural autoantibodies are primarily polyreactive antibodies with low affinity for a specific set of autoantigens.
[0046] Monoclonal antibodies are heterologous antibodies that recognize a specific antigenic epitope and are produced by a single B cell clone [Lipman NS1, Jackson LR, Trudel LJ, Weis-Garcia F. Monoclonal versus polyclonal antibodies: distinguishing characteristics, applications, and information resources. ILAR J. 2005;46(3):258-68. / / IHC Staining Methods. Fifth edition. Preface Chapter 1. Thomas Boenisch. Antibodies. p:1-9]. Monoclonal antibodies can be produced using hybridoma technology. The process begins with immunization based on previously developed techniques used to produce polyclonal antisera. Further steps in the process are performed to grow hybrid cells that produce monospecific antibody clones. Their individual isolation is performed using the same methods as for polyclonal antisera.
[0047] Polyclonal antibodies are represented by a collection of immunoglobulins that recognize multiple epitopes of a specific antigen and are secreted by different B cell lines in the body [Lipman NS1, Jackson LR, Trudel LJ, Weis-Garcia F. Monoclonal versus polyclonal antibodies: distinguishing characteristics, applications, and information resources. ILAR J. 2005;46(3):258-68. / / IHC Staining Methods. Fifth edition. Preface Chapter 1. Thomas Boenisch. Antibodies. p:1-9]. Polyclonal antibodies can be produced by active immunization of animals. For immunization, the animal is given an injection of a suitable compound required by the invention, i.e. the antigen, according to a developed injection protocol. As a result, this procedure gives a monospecific antiserum containing a high concentration of antibodies that are used in a method of multiple serial dilutions to obtain the final product. Affinity purification of the antibodies present in the antiserum can be carried out, for example, using differential precipitation or ion exchange chromatography, if necessary.
[0048] In view of the above, the term "antibody" means an immunoglobulin (natural, polyclonal or monoclonal antibody) of any origin that specifically binds to a target molecule (antigen). Specificity, i.e. the ability of an antibody to recognize and interact with a specific type of antigen epitope, is the main characteristic of an antibody that defines the full range of its effects [Boyd WC. Fundamentals of immunology. Fundam. Immunol. 1946; Langman RE. The specificity of immunological reactions. Mol. Immunol. 2000; 37: 555-561]. Specificity does not depend on the nature of the antibodies or their production methods, as natural, polyclonal or monoclonal antibodies of the same specificity affect the same target [А. Roitt et al., Essential Immunology. Translated from English. - Moscow: Mir, 2000, p.149-161, 527-544] and therefore they can be used to produce the claimed medicine.
[0049] In one embodiment, the claimed pharmaceutical can be prepared using polyclonal antibodies as a matrix (stock) solution at a concentration of 0.5÷5.0 mg / ml for technical processing performed by multiple serial dilutions of the antibody stock material to obtain the final product.
[0050] The technical process, i.e. the method of multiple serial dilutions of antibody stock material, is a deliberate reduction in concentration by serial dilutions of 9 parts (for a 10-fold dilution, D) or 99 parts (for a 100-fold dilution, C) or 999 parts (for a 1000-fold dilution, M) of a neutral solvent combined with an external mechanical action (e.g. shaking) applied to each of the resulting dilutions, a new container being used for each serial dilution [see W. Shwabe “Homeopathic medicines”, Moscow, 1967, p.14-29].
[0051] The seemingly simple procedure of repeatedly and successively decreasing the concentration of a substance has proven to be a complex technology that provides products with unique properties. Historically, the products of potentization technology have been called "low doses," "enhanced preparations," or "high dilutions."
[0052] The final product can be produced in various dosage forms [OFS.1.6.2.001.18, the State Pharmacopoeia of the Russian Federation, ed. XIV] and can contain pharma- ceutically acceptable excipients.
[0053] For example, the claimed pharmaceuticals can be prepared as solid dosage forms containing the requisite (effective) amount of pharma- ceutical acceptable excipients, which are neutral carriers (e.g., lactose) impregnated with a mixture of technical preparations resulting from multiple serial dilutions of antibody stock material, such as antibodies against HLA-DRB1, β2-MG, IFN-γ, CD4, and pharma- ceutical acceptable excipients, such as hypromellose, maltitol, glycerol, potassium sorbate, anhydrous citric acid, isomalt, silicon dioxide, sodium cyclamate, sodium saccharin, microcrystalline cellulose, magnesium stearate, and the like.
[0054] The final product of the present invention is a pharmaceutical product which is a technical process resulting from multiple serial dilutions of stock materials: a) antibodies against the β1 domain of major histocompatibility complex class II molecules (HLA-DRB1) and b) antibodies against β2-microglobulin (β2-MG), or a) antibodies against the β1 domain of major histocompatibility complex class II molecules (HLA-DRB1), b) antibodies against β2-microglobulin (β2-MG), c) antibodies against interferon gamma (IFN-γ), and d) antibodies against CD4. The dilutions of the stock materials used vary from 10-fold (D) to 1000-fold (M). The optimal dilutions and ratios of the starting components are determined according to known principles of pharmacodynamics and pharmacokinetics, in particular dose-response curves.
[0055] The solid oral dosage forms of the claimed pharmaceutical are prepared by mixing in a fluidized bed system (e.g., Huttlin Pilotlab by Huttlin GmbH) a prepared aqueous or aqueous alcoholic solution of the technical process resulting from multiple serial dilutions of the antibody stock material (concentrations are selected empirically, OFS.1.6.2.0010.18, State The technical product is prepared by spraying a mixture of 100% glycerol (pharmacopoeia) onto a neutral carrier granule, i.e. lactose (milk sugar), which is simultaneously dried by an upward flow of heated air below 40° C. The resulting tablet blend is mixed homogeneously and then compressed by dry direct compression (e.g. in an XL400 tablet press by Korsch) [WO 2007105981 (А1) (September 20, 2007)]. The compression process results in 300 mg tablets impregnated with an aqueous or hydroalcoholic solution of the technical product obtained from several serial dilutions of the stock material, i.e. antibodies against HLA-DRB1, antibodies against β2-microglobulin, antibodies against interferon gamma, and / or antibodies against CD4.
[0056] The following drawings, together with the accompanying drawings, are given to explain the present invention. [Brief description of the drawings]
[0057] [Figure 1] Figure 1. Bladder weights 7 days after infection.
[0058] [Diagram 2] Figure 2. Bladder bacterial burden in mice 7 days post-infection.
[0059] [Diagram 3] Figure 3. Kidney weights at 7 days post-infection.
[0060] [Figure 4] Figure 4. Kidney bacterial burden in mice 7 days post-infection.
[0061] [Diagram 5] Figure 5. Bacterial load in urine on days 1, 3, and 6 postinfection.
[0062] [Figure 6] Figure 6. Survival rate (%) of mice after infection with E. coli with a dose of 2LD100 (point 0 on the horizontal axis). Note: * - difference from the control group is statistically significant, p<0.05; # - difference from the enrofloxacin group is statistically significant, p<0.05.
[0063] [Figure 7] FIG. 7. Mouse body weight (M±m) as a marker of antibacterial activity of the combination of the claimed drug with AMC after infection with AMC-resistant Klebsiella pneumoniae strain BAA-1705 (point 0 on the horizontal axis) at a dose of 106 CFU / mouse.
[0064] [Figure 8] Fig. 8. Mouse survival rate (%) as a marker of antibacterial activity of the combination of the claimed drug with AMC after infection (point 0 on the horizontal axis) with AMC-resistant Klebsiella pneumoniae strain BAA-1705 at a dose of 106 CFU / mouse. Note: * - difference from the control group is statistically significant, p<0.05; # - difference from the control+AMC group is statistically significant, p<0.05; $ - difference from the AMC group is statistically significant, p<0.05.
[0065] [Figure 9] Figure 9. Bacterial susceptibility (inhibition %) to AMC50% inhibitory concentration (IC50, M±m) (Klebsiella pneumoniae BAA-1705 strain, 5×104 CFU / well) and AMC100% inhibitory concentration for intact bacteria and bacteria isolated from animals administered test substances in vivo. Note: * - Difference from the value for "intact bacteria" is statistically significant.
[0066] [Figure 10]Figure 10. Edema weight (M ± m) as a marker of anti-inflammatory activity of the claimed drug in a model of carrageenan-induced paw edema in rats. Note: * - difference from control group is statistically significant, p < 0.05; # - difference from indomethacin group is statistically significant, p < 0.05.
[0067] [Figure 11] Figure 11. Comparison of the number of CFU of JB270 and JB271[StrepR] per gram of spleen in mice on days 2-4 after infection with a streptomycin-susceptible Salmonella strain (JB270) plus a streptomycin-resistant Salmonella strain (JB271[StrepR]) (1:1 at a dose of 5.0 log10 CFU / mouse). Data are expressed as M ± SE. *p<0.05 vs values obtained for the same groups on days 2 and 3 of the study; #p<0.05 vs values obtained for groups 1 and 3 on days 2, 3, 4, and 5 of the study (days 1, 2, 3, and 4 post-infection, respectively).
[0068] [Figure 12] Figure 12. Comparison of JB270 CFU counts per gram of spleen from mice on days 2-4 post-infection with a nalidixic acid-susceptible (JB270) + resistant (JB285[Na]R) strain (1:1 at a dose of 5.0 log10 CFU / mouse). Data are expressed as M ± SE. *p<0.05 vs values obtained for the same groups on day 3 of the study; #p<0.05 vs values obtained for groups 4 and 6 on days 3, 4, and 5 of the study (days 2, 3, and 4 post-infection, respectively) and for group 4 on day 2 of the study.
[0069] [Figure 13] Figure 13. Mouse survival rate (%) as a marker of antibacterial activity of the claimed drug after infection (point 0 on the horizontal axis) with Clostridium perfringens (ATCC 13124) (1010 CFU / mouse) by the intraperitoneal route. *p<0.05 vs values obtained in groups 1, 2, 4, and 5; #p<0.05 vs values obtained in groups 1, 4, and 5; $p<0.05 vs values obtained in groups 1 and 5.
[0070] [Figure 14] Figure 14. Mouse survival rate (%) as a marker of antibacterial activity of the claimed drug in the treatment of animals infected (point 0 on the horizontal axis) by the intratracheal route with Chlamydophila pneumonia (CM1) (1.5*106 CFU / mouse). *p<0.05 vs values obtained in groups 1 and 2; #p<0.05 vs values obtained in group 1.
[0071] [Figure 15] Figure 15. Number of HEp2 cells infected with Chlamydophila pneumonia (strain CM1) after 72 h incubation with lung tissue homogenates obtained from mice administered placebo, the claimed drug, or azithromycin on days 3, 6, and 12 after infection by the intratracheal route with the same bacteria (1.5*106 CFU / mouse). Data are expressed as % of control-1 (placebo), M±SE. *p<0.05 vs values obtained in group 1 (placebo) on the same day of the study; #p<0.05 vs values obtained in group 2 (drug) on the same day of the study.
[0072] [Figure 16] FIG. 16. Interleukin-1β concentration in lung tissue as a marker of immunotropic activity of the claimed drug in the treatment of animals infected (point 0 on the horizontal axis) with Chlamydophila pneumonia (CM1) (1.5*106 CFU / mouse) by the intratracheal route. Data are expressed as M±SE. p<0.05 vs background values (intact); #p<0.05 vs values obtained in group 1 (placebo); $p<0.05 vs values obtained in group 2 (drug). Comparisons between groups were made within a single time point (study day).
[0073] [Figure 17]Figure 17. Interleukin-6 concentration in lung tissue as a marker of immunotropic activity of the claimed drug in the treatment of animals infected (point 0 on the horizontal axis) with Chlamydophila pneumonia (CM1) (1.5*106 CFU / mouse) by the intratracheal route. Data are expressed as M±SE. p<0.05 vs background values (intact); #p<0.05 vs values obtained in group 1 (placebo); $p<0.05 vs values obtained in group 2 (drug). Comparisons between groups were made within a single time point (study day).
[0074] [Figure 18] Figure 18. Effect of treatment on TNF-α concentration in lung tissue of mice infected (point 0 on horizontal axis) with Chlamydophila pneumonia (CM1) (1.5*106 CFU / mouse) via the intratracheal route. Data are expressed as M±SE.
[0075] [Figure 19] Figure 19. Mouse survival rate (%) as a marker of antibacterial activity of the claimed drug in the treatment of neutropenic animals infected (point 0 on the horizontal axis) with Klebsiella pneumoniae strain 8637 (2*107 CFU / mouse) via the intranasal route. *p<0.05 vs. values obtained with the control (placebo).
[0076] [Figure 20] Figure 20. Bacterial load in blood and organs of mice infected (point 0 on the horizontal axis) with Klebsiella pneumoniae strain 8637 (2*107 CFU / mouse) via the intranasal route. *p<0.05 vs. values obtained with the control (placebo).
[0077] [Figure 21]Figure 21. Effect of Drug 1 and Drug 2 on the number of CFU of S. pneumoniae in mouse lungs after sequential infection with A / New Jersey / 8 / 76 (H1N1) virus and S. pneumoniae. Note: * - difference from "Model control" group is statistically significant, p<0.05; # - difference from "Untreated control" group and "Control" group is statistically significant, p<0.05; $ - difference from "Drug 1" group is statistically significant, p<0.05.
[0078] [Figure 22] Figure 22. Survival rate (%) of mice after infection (point 0 on the horizontal axis) with H1N1 / A California 04 / 2009 influenza virus and Staphylococcus aureus (strain 1986). Note: * - difference from the control group is statistically significant, p<0.05; # - difference from the negative control group is statistically significant, p<0.05.
[0079] [Figure 23] Figure 23. Changes in the relative bronchial hypersensitivity in mice infected with RSV (A2 strain). Note: In this figure, the bronchial hypersensitivity data per group at the point "0 mg / ml methacholine" (baseline) was set to 1. Values obtained at other points were normalized to the baseline of the corresponding group. Data are expressed as normalized M ± CI 95%. * - difference from the intact group (group 6) is statistically significant, p < 0.05; # - difference from the control group (group 3) is statistically significant, p < 0.05; and - difference from the RSV group (group 4) is statistically significant, p < 0.05.
[0080] [Figure 24] Figure 24. Viral RNA copy number (M ± m) in the lungs of mice infected with RSV (A2). Note: * - difference from control (group 3) and RSV (group 4) groups is statistically significant, p < 0.05; # - difference from group 6 is statistically significant, p < 0.05, $ - difference from group 2 is statistically significant, p < 0.05.
[0081] [Diagram 25] Figure 25. Body weight of rats infected with Pseudomonas aeruginosa (RP73) at a dose of 6.5*107 CFU / ml by intratracheal route, administered placebo, the claimed drug, or tobramycin as therapeutic and prophylactic therapy. Data are expressed as M±SE. *p<0.05 vs values obtained in group 1 (untreated animals) and group 2 (placebo); #p<0.05 vs values obtained in group 4 (drug).
[0082] [Figure 26] Figure 26. Bacterial burden in the lungs of rats administered placebo, the claimed drug, or tobramycin as curative and prophylactic therapy 5 days after intratracheal infection with Pseudomonas aeruginosa (RP73) at a dose of 6.5*107 CFU / ml. Data are expressed as % of the values obtained in group 1 (untreated animals), M±SE. *p<0.05 vs values obtained in group 1 (untreated animals) and group 2 (placebo).
[0083] [Figure 27] Figure 27. Bacterial load in bronchoalveolar lavage fluid of rats administered placebo, the claimed drug, or tobramycin as therapeutic and prophylactic therapy 5 days after intratracheal infection with Pseudomonas aeruginosa (RP73) at a dose of 6.5*107 CFU / ml. Data are expressed as % of the value obtained in group 1 (untreated animals), M ± SE. *p<0.05 vs values obtained in group 1 (untreated animals) and group 2 (placebo); #p<0.05 vs values obtained in group 4 (drug).
[0084] [Figure 28] Figure 28. Bacterial load in the fluid in chambers implanted subcutaneously in mice 4 days after in vivo infection with Porphyromonas gingivalis (ATCC 33277) at a dose of 108 CFU / animal. Data are expressed as M ± SE. *p<0.05 vs values obtained in group 1 (untreated animals) and group 2 (placebo).
[0085] [Figure 29]Figure 29. Interleukin-1β concentrations in subcutaneously implanted chambers of mice 4 days after in vivo infection with Porphyromonas gingivalis (ATCC 33277) at a dose of 108 CFU / animal. Data are expressed as M ± SE. *p<0.05 vs values obtained in group 1 (untreated animals) and group 2 (placebo).
[0086] [Diagram 30] Figure 30. Interleukin-6 concentration in subcutaneously implanted chambers of mice 4 days after in vivo infection with Porphyromonas gingivalis (ATCC 33277) at a dose of 108 CFU / animal. Data are expressed as M ± SE*. p<0.05 vs values obtained in group 1 (untreated animals) and group 2 (placebo).
[0087] [Diagram 31] Figure 31. Bacterial burden in the lungs of mice infected with Mycobacterium tuberculosis (H37Rv) at 5*106 CFU / animal and 4 weeks after treatment with placebo, the claimed drug, or the combination of isoniazid + rifampicin + ethambutol azithromycin. Data are expressed as M±SE. *p<0.05 vs values obtained in group 1 (untreated animals) and group 2 (placebo).
[0088] [Diagram 32] Figure 32. Percentage of patients without ARVI symptoms (confirmed by clinical diagnosis including PCR). PP analysis data. EXAMPLES
[0089] Example 1 Induced in guinea pigs Mycobacterium Tuberculosis Antitubercular activity of the claimed drug against
[0090] The objective of the study was to compare the efficacy and safety of cyclosporine in a guinea pig model of experimental tuberculosis compared with the antituberculous drug isoniazid. Mycobacterium TuberculosisThe object of the present invention is to investigate the antituberculous activity of the drug against HLA-DRB1. The drug of the present invention comprises a technical preparation obtained by serial dilution of a stock material of an antibody against HLA-DRB1 (C12C150 hydroalcoholic dilution of a monoclonal antibody against HLA-DRB1 in a ratio of 2:3) and a technical preparation obtained by serial dilution of a stock material of an antibody against β2-MG (C12C150 hydroalcoholic dilution of a monoclonal antibody against β2-MG in a ratio of 2:3) in a volume ratio of 1:2.
[0091] A) Technical treatment (2.5 mg / ml) resulting from a serial dilution of a stock material of a monoclonal antibody against the β1 domain of the major histocompatibility complex class II molecule (HLA-DRB1) obtained by combining two different serial dilutions of a stock (matrix) solution of a monoclonal antibody against HLA-DRB1 in an aqueous alcoholic solvent. The following dilutions were mixed in a volume ratio of 2:3: 1) While shaking each dilution, 12 A 2-fold diluted stock (matrix) solution (equivalent to a C12 dilution). 2) While shaking each dilution, 150 A 2-fold diluted stock (matrix) solution (equivalent to a C150 dilution).
[0092] B) Technical treatment (1.0 mg / ml) resulting from a serial dilution of a stock material of a monoclonal antibody against β2-microglobulin (β2-MG) obtained by combining two different serial dilutions of a stock (matrix) solution of a monoclonal antibody against β2-MG in an aqueous solvent. The following dilutions were mixed in a volume ratio of 2:3: 1) While shaking each dilution, 12 A 2-fold diluted stock (matrix) solution (equivalent to a C12 dilution). 2) While shaking each dilution, 150 A 2-fold diluted stock (matrix) solution (equivalent to a C150 dilution).
[0093] Experimental Group: Group 1 - Intact control, uninfected animals (n=7)
[0094] Group 2 - Negative control (infected untreated animals) (n=7)
[0095] Group 3 - Animals (n=14) that received placebo (purified water) orally at a volume of 4 ml / kg twice daily for 6 days a week for 5 days before infection and for 2 weeks to 2 months after infection.
[0096] Group 4 - Animals (n=14) that received placebo (purified water) in a volume of 4 ml / kg orally twice daily, 6 days per week, for 5 days before infection and for 2 weeks to 2 months after infection, and received isoniazid at a dose of 10 mg / kg in a volume of 0.4 ml, 6 days per week, for 2 weeks to 2 months after infection.
[0097] Group 5 - Animals (n=14) that received drug orally in a volume of 4 ml / kg twice daily for 6 days a week for 5 days before infection and for 2 weeks to 2 months after infection.
[0098] Test Design: The duration of the study was 196 days (6.5 months): September-December - treatment and follow-up of the experimental animals; January-March - analysis of necropsy samples by microbiological and histological methods. Physical and visual examinations, health assessments, and mortality monitoring were performed daily before feeding.
[0099] The test substances were administered orally to the guinea pigs with a needleless syringe in a total volume of 8 ml / kg twice a day for 6 days a week (every day except Sunday) for 5 days before infection and for 2 months after infection. The dose of the test substance was adjusted once a week based on the body weight of the animals. Isoniazid suspended in water and starch was administered to the animals according to the same regimen and at the same time intervals as the test substance. The dose of isoniazid was 10 mg / kg body weight in 0.4 ml of water-starch slurry.
[0100] Mortality, body weight, and medium Mycobacterium Tuberculosis The proliferation of guinea pigs and histological changes in animal organs were evaluated in all groups of guinea pigs throughout the study. Test results: Table 1. Guinea pig organ evaluation [Table 1]
[0101] Conclusion: Based on the obtained test results, it can be concluded that the isoniazid group and the group of the claimed drug showed the same positive therapeutic effect. Histological examination of the organs of the animals of these two groups showed signs of therapeutic pathomorphology. The claimed drug also showed efficacy against pulmonary infections.
[0102] Example 2 Antibacterial activity of the claimed drug against Streptococcus pyogenes in mice with and without antibiotics
[0103] This is a blinded placebo-controlled study. The purpose of the study is to evaluate the efficacy of the claimed medicament with or without linezolid (synthetic antibiotic) or telithromycin (ketolide antibiotic) against Streptococcus pyogenes in a model of soft tissue infection in neutropenic mice. The medicament of the invention comprises a technical preparation obtained from serial dilutions of a stock material of antibodies against HLA-DRB1 (monoclonal antibodies in С4D20 hydroalcoholic dilutions (2.5 mg / ml) in a ratio of 3:2) and a technical preparation obtained from serial dilutions of a stock material of antibodies against β2-MG (natural antibodies in С10C150 hydroalcoholic dilutions (2.5 mg / ml) in a ratio of 1:2) in a volume ratio of 2:3.
[0104] Experimental Group: Group 1 - negative control female mice infected with Streptococcus pyogenes and received no medication or antibiotics during the study; n=3
[0105] Group 2 - Female mice were orally administered placebo (glycine buffer) at a volume of 20 ml / kg daily for 5 days prior to infection with S. pyogenes and on the day of infection; n=6
[0106] Group 3 - female mice received daily oral administration of placebo (glycine buffer) at a volume of 20 ml / kg for 5 days before and on the day of infection with S. pyogenes, combined with linezolid (50 mg / kg) at 2 and 14 hours after infection; n=6
[0107] Group 4 - female mice received daily oral administration of placebo (glycine buffer) at a volume of 20 ml / kg for 5 days before and on the day of infection with S. pyogenes, combined with telithromycin (10 mg / kg) at 2 and 14 hours after infection; n=6
[0108] Group 5 - female mice were orally administered the drug at a volume of 20 ml / kg daily for 5 days prior to and on the day of infection with S. pyogenes; n=6
[0109] Group 6 - female mice received daily oral administration of the drug in a volume of 20 ml / kg for 5 days before and on the day of infection with S. pyogenes, combined with linezolid (50 mg / kg) 2 and 14 hours after infection; n=6
[0110] Group 7 - female mice were orally administered the drug in a volume of 20 ml / kg daily for 5 days before and on the day of infection with S. pyogenes, combined with telithromycin (10 mg / kg) at 2 and 14 hours after infection; n=6
[0111] Test Design: The study period was 7 days. Neutropenia was induced in mice by two intraperitoneal injections of cyclophosphamide (150 mg / kg on day 4 before infection and 100 mg / kg on day 1 before infection). No further immunosuppression was administered to the immunocompromised mice during the study.
[0112] Test samples were administered orally at a dose of 20 ml / kg for 5 days prior to infection and at 2 and 14 hours after infection (on the day of infection). On the day of infection, mice were infected with S. pyogenes (ATCC BAA-2469) at a dose of 5.4 lg CFU by intramuscular injection in the thigh. Additionally, animals were administered antibiotics, namely, linezolid 50 mg / kg and telithromycin 10 mg / kg, to which S. pyogenes BAA-2469 is sensitive and resistant, respectively.
[0113] Animal survival, clinical signs of infection, and body weight were assessed in all groups of mice throughout the study.
[0114] Test Design: At 2 h postinfection, bacterial load analysis (CFU / g, log 10 Thigh muscles were collected from untreated mice (group 1) for immunization with IgG. In the other groups, thigh muscles were collected 24 h post-infection to assess the bacterial load. The data obtained are shown in Table 2. Table 2. Mean bacterial load in thigh tissue (CFU / g, log10) [Table 2]
[0115] Conclusion: A statistically significant reduction in the mean bacterial load was recorded in combination with Linezolid in the test groups (Groups 3 and 6) 24 hours after infection. Thus, the claimed drug was found to be effective against musculoskeletal infections and enhance their efficacy when co-administered with antibiotics.
[0116] Example 3 Efficacy of the claimed drug alone and in combination with an antibiotic against E. coli in a mouse model of urinary tract infection
[0117] The aim of the study is to evaluate the efficacy of the test drug with and without the antibiotic norfloxacin in an experimental model of E. coli infection in mice.The drug of the invention comprises a technical preparation (aqueous dilution in C12C30C50 (2.5 mg / ml) of polyclonal antibodies in a ratio of 1:1:1) obtained from serial dilutions of a stock material of antibodies against HLA-DRB1 and a technical preparation (aqueous dilution in C12C30C50 (2.5 mg / ml) of monoclonal antibodies in a ratio of 1:1:1) obtained from serial dilutions of a stock material of antibodies against β2-MG in a ratio of 1:1:1 in a ratio of 1:1:1.
[0118] Experimental Group: Group 1 - Male and female mice (n=10) administered the claimed drug daily at 20 ml / kg by oral gavage for 5 days before and 7 days after infection and 1 hour after infection (volume 10 ml / kg) by intraperitoneal route.
[0119] Group 2 - Male and female mice (n=10) administered the claimed drug at 20 ml / kg daily by oral gavage for 5 days before infection and 7 days after infection, and norfloxacin at 5 mg / kg (volume 10 ml / kg) by intraperitoneal route 1 hour after infection.
[0120] Group 3 - Male and female control mice (n=10) administered glycine buffer daily at 20 ml / kg by oral gavage for 5 days before and 7 days after infection, as well as 1 hour after infection (volume 10 ml / kg) by intraperitoneal route.
[0121] Group 4 - Male and female mice (n=10) that received glycine buffer at 20 ml / kg daily by oral gavage for 5 days before infection and 7 days after infection, and norfloxacin at 5 mg / kg (volume 10 ml / kg) by intraperitoneal route 1 hour after infection.
[0122] Test Design: Mice were infected by intraurethral inoculation of E. coli UTI89 (2.107 CFU / mouse) into the bladder (day 0).
[0123] Urine was collected for CFU quantification on days 1, 3, and 6 post-infection. On day 7 post-infection, 10 animals from each group were sacrificed and kidneys and bladders were collected for bacterial load analysis. Body weights were recorded every 2 days throughout the experiment.
[0124] Test Design: Body weight showed positive changes in all groups, indicating that the test samples were well tolerated by the animals.
[0125] Bladder weight was significantly lower in Group 2 (medicine + norfloxacin) compared to Group 4 (glycine buffer + norfloxacin), which may suggest that the claimed medicine in combination with antibiotics can reduce bladder distension.
[0126] The claimed drug in combination with norfloxacin (group 2) significantly reduced the bacterial load in the bladder, and therefore this combination may have potential as a therapeutic regimen (Figures 1, 2).
[0127] No statistically significant differences in kidney weights were observed between groups.
[0128] The claimed drug in combination with norfloxacin (group 2) significantly reduced the bacterial burden in the kidney compared with glycine buffer (group 3). Therefore, this combination may have potential as a therapeutic regimen (Figures 3, 4).
[0129] Beginning on day 3, urine samples from Group 2 (medicine + norfloxacin) showed reduced bacterial load compared to Group 4 (glycine buffer + norfloxacin). Urine samples from Group 3 (glycine buffer) had higher numbers of CFU at all time points compared to Group 1 (medicine) (Figure 5).
[0130] Conclusion: Thus, the claimed medicament in combination with the antibiotic norfloxacin exerts antibacterial activity against E. coli in a mouse model of urinary tract infection.
[0131] Example 4 In chickens Salmonella enteritidis rif92 Antibacterial activity of the claimed drug with and without antibiotics against
[0132] This is a blinded, placebo-controlled study. The purpose of this study was to Salmonella enteritidis rif92 The present invention relates to a drug that is effective against the following two types of technical preparations: 1) antibodies against the β1 domain of major histocompatibility complex class II molecules and 2) antibodies against the β2-microglobulin of major histocompatibility complex class I molecules, obtained by serial dilutions (C12C30C50 dilutions) of a stock material of affinity-purified polyclonal antibodies in equal amounts. A) Technical treatment (2.5 mg / ml) resulting from serial dilutions of a stock material of polyclonal antibodies against the β1 domain of major histocompatibility complex class II molecules (HLA-DRB1) obtained by combining three different serial dilutions of a stock (matrix) solution of polyclonal antibodies against HLA-DRB1 in hydroalcoholic solvent. The following dilutions were mixed in a 1:1:1 ratio: 1) While shaking each dilution, 12 A 2-fold diluted stock (matrix) solution (equivalent to a C12 dilution). 2) While shaking each dilution, 30 A 2-fold diluted stock (matrix) solution (equivalent to a C30 dilution). 3) While shaking each dilution, 50 A 2-fold diluted stock (matrix) solution (equivalent to a C50 dilution). B) Technical treatment (2.5 mg / ml) resulting from a serial dilution of a stock material of a monoclonal antibody against β2-microglobulin (β2-MG) obtained by combining three different serial dilutions of a stock (matrix) solution of a polyclonal antibody against β2-MG in aqueous solvent. The following dilutions were mixed in a 1:1:1 volume ratio: 1) While shaking each dilution,12 A 2-fold diluted stock (matrix) solution (equivalent to a C12 dilution). 2) While shaking each dilution, 30 A 2-fold diluted stock (matrix) solution (equivalent to a C30 dilution). 3) While shaking each dilution, 50 A 2-fold diluted stock (matrix) solution (equivalent to a C50 dilution).
[0133] Experimental Group: Group 1- Salmonella enteritidis Male and female chickens (n=15) infected with B. typhimurium and administered the medicament of the present invention intragastrically at a dose of 0.2 ml / animal / day from 4 to 9 days of age.
[0134] Group 2- Salmonella enteritidis Male and female chickens (n=15) infected with B. avium and administered intragastrically with the medicament of the invention at a dose of 0.2 ml / animal / day from 4 to 9 days of age and intragastrically with ciprofloxacin (Ciprovet, OOO Research Innovation Center "Agrovetzashchita", antibiotics) at a dose of 0.5 mg / kg body weight (ED50) from 5 to 9 days of age. The pharmaceutical composition of the invention and the antibiotics were administered at 1 hour intervals. During the study, the chickens gained weight every day, so the amount of antibiotics was calculated every day before administration.
[0135] Group 3- Salmonella enteritidis Male and female chickens (n=15) were infected with and intragastrically administered placebo (purified water) at a dose of 0.2 ml / animal / day from 4 to 9 days of age.
[0136] Group 4- Salmonella enteritidis Male and female chickens (n=15) were infected with B. avium and intragastrically administered placebo (purified water) at a dose of 0.2 ml / animal / day from 4 to 9 days of age, and intragastrically administered ciprofloxacin at a dose of 0.5 mg / kg body weight (ED50) from 5 to 9 days of age. The test samples and antibiotics were administered 1 hour apart.
[0137] Group 5 - Intact control animals - male and female uninfected and untreated chickens (n=15).
[0138] Test Design: The study period was 12 days (from day 1 to day 12 of age). The chickens were isolated for the first 2 days. On the third day, all birds except for group 5 were given twice the lethal dose of Salmonella enteritidis (Serotype rif92, 2.5 × 10 in 0.5 ml / animal) 9 CFU / g) via intraperitoneal route. From 4 to 9 days of age, chickens were administered either the claimed drug or purified water. From 5 to 9 days of age, chickens were administered Ciprovet (groups 2 and 4).
[0139] Throughout the study, the following parameters were examined: survival rate; body weight; feed conversion ratio (weight of feed intake by the end of the experiment normalized to the body weight gained by the animals); and changes in the gastrointestinal tract and liver of chickens. S. enteritidis rif92 Presence and concentration of. statistical analysis
[0140] Statistical analysis of the obtained data was performed using the Kruskal-Wallis test combined with post-hoc Wilcoxon test and a two-way generalized linear model combined with post-hoc Tukey test (Gamma distribution with data normalized at 100 was used for percentages and logarithmic transformation of other parameters). Differences were considered statistically significant when p<0.05.
[0141] Test results: The results obtained showed that the survival rate of all experimental groups was 100%. The maximum live weight recorded in broilers treated with the claimed drug (group 1) at the end of the study exceeded the maximum live weight of the corresponding placebo (group 3) and intact (group 5) groups by 33.9 g and 38.7 g, respectively. Feed conversion ratio was similar between the groups. Basic parameters of blood tests showed no differences between the groups.
[0142] Summary data on Salmonella counts in liver and intestinal contents per group at the end of the study are shown in Table 3. Table 3. Presence of Salmonella after slaughter and antimicrobial activity index (AAI) [Table 3]
[0143] The antibacterial activity index (AAI) was calculated using the following formula: AAI=Bc / Bt (where Bc - number of bacterial cells in organ homogenates of the control group until the end of the follow-up period; Bt - number of bacterial cells in organ homogenates of the test group until the end of the follow-up period) [Okhapkina VY, Pyatkova NV, Fedotov AK Express efficacy assessment method for antibacterial agents in experimental brucellosis / / Challenges of Highly Infectious Diseases, 2016; 2:79-82.].
[0144] According to the data in Table 1, the lowest Salmonella counts in the liver were recorded in groups 2 and 4, while the highest Salmonella counts were observed in group 3. Meanwhile, the AAI of the inventive drug (group 1) (10.6) was significantly higher than that of the combination with antibiotics (3.6). In groups 1 and 2, the liver bacterial load was 10.6 and 3.5 times lower than in groups 3 and 4, respectively, suggesting a protective effect of the drug on the liver in terms of Salmonella counts.
[0145] Conclusion: 1. The claimed medicine showed efficacy (antibacterial effect) characterized by a 33.4% reduction in the number of diseased chickens compared to the placebo group and a 10.6-fold reduction in the bacterial load in the liver of the medicine group compared to the placebo group. This suggests a protective effect of the medicine on the liver in terms of Salmonella cell counts. The claimed medicine is also effective against intestinal infections. 2. The drug co-administered with antibiotics at ED50 in chickens improved the efficacy of the latter, as a significant reduction in bacterial load in the digestive tract was observed at the time of sacrifice, compared with the drug and placebo groups. Thus, it was confirmed that the effective dose of antibiotics could be reduced when co-administered with the claimed drug.
[0146] Example 5 In mice Escherichia coli CN 160 Antibacterial activity of the claimed drug with and without antibiotics against
[0147] This is a blinded, placebo-controlled study. The purpose of this study is to E. coli CN 160 The aim of this study is to evaluate the pharmacological effect of the test drug in combination with enrofloxacin therapy (Baytril, Bayer) in experimental infections caused by B. cerevisiae. The drug of the invention contains equal amounts of two technical preparations obtained from serial dilutions (C12C30C50 dilutions) of a stock material of affinity-purified polyclonal antibodies: 1) antibodies against the β1 domain of major histocompatibility complex class II molecules (2.5 mg / ml) and 2) antibodies against the β2-microglobulin of major histocompatibility complex class I molecules (2.5 mg / ml).
[0148] Experimental Group: Group 1 - Male and female mice (n=10) administered the claimed drug orally once daily at a dose of 10 ml / kg / day for 5 days prior to infection, 1 hour post-infection and for the following 14 days.
[0149] Group 2 - Male and female control mice (n=10) that received placebo (purified water) orally once daily at a dose of 10 ml / kg / day for 5 days prior to infection, 1 hour after infection, and for the following 14 days.
[0150] Group 3 - Male and female mice (n=10) administered Baytril (an antibacterial agent) intramuscularly at a dose of 1.38 mg / kg for 3 days before and 3 days after infection.
[0151] Group 4 - Male and female mice (n=10) administered the claimed drug orally once daily at a dose of 10 ml / kg / day for 5 days prior to infection, 1 hour after infection, and for the following 14 days, and co-administered Baytril (antibacterial agent) by intramuscular injection at a dose of 1.38 mg / kg for 3 days prior to infection and 3 days after infection.
[0152] Test Design: Test substances were administered orally once a day for 5 days before infection with E. coli, 1 h after infection (day 6), and then for 14 days during the follow-up period (total of 20 days). On day 6, mice were infected by a single intraperitoneal injection with a dose of 2LD100, previously determined in a preliminary study (LD100 = 7.3 × 10 8 The antibiotic Baytril was administered intramuscularly at a given EF50, i.e., 1.38 mg / kg, for 3 days before and 3 days after infection (total of 6 days).
[0153] Mortality was assessed in all groups of mice throughout the study.
[0154] Statistical analysis: Statistical analysis of the findings was performed using Kaplan Meier curves followed by pairwise comparisons with the log-rank test. Differences were considered statistically significant when p<0.05.
[0155] Test results: All animals in each group, except for the mice administered the combination of the claimed drug and Baytril (Group 4), died at a lethal dose. Escherichia coli After infection with , death occurred within 4 days (Figure 6). The highest mortality (70-80%) was observed during the first 2 days after infection.
[0156] Conclusion: E. coliIn mice infected with 2LD100 of CN 160, the use of the claimed drug in combination with the ED50 of Baytril prevented the death of 50% of the animals; E. coli The combination shows a significant antibacterial effect against 2 times the lethal dose of CN-160.Therefore, in this test, it was found that the co-administration of the claimed medicament of the present invention with antibiotics improves the pharmacological effect of the antibiotics.Furthermore, the combination was also shown to reduce the effective dose of antibiotics.
[0157] The claimed medicine has also been found to be effective against systemic infections including sepsis.
[0158] Example 6 Resistant to amoxicillin / clavulanic acid Klebsiella Pneumonia Efficacy of drugs against infection of mice with BAA-1705 strain
[0159] The purpose of this study is to: Klebsiella Pneumonia The aim of this study is to investigate the antibacterial activity of the claimed drug in combination with amoxicillin plus clavulanic acid (AMC) against AMC-resistant strains of B. cerevisiae. The drug of the present invention contains equal amounts of two technical preparations obtained from serial dilutions (C12C30C50 dilutions) of a stock material of affinity-purified polyclonal antibodies: 1) antibodies against the β1 domain of major histocompatibility complex class II molecules (2.5 mg / ml) and 2) antibodies against the β2-microglobulin of major histocompatibility complex class I molecules (2.5 mg / ml).
[0160] Test No. 1
[0161] Experimental Group: Group 1 - Male mice (n=15) administered the combination of the claimed drug + AMC intragastrically at a dose of 25 mg / kg in 10 ml / kg of 0.9% NaCl for 5 days before infection and intragastrically at a dose of 10 ml / kg / day 1 hour after infection.
[0162] Group 2--control male mice (n=15) that received purified water intragastrically at a dose of 10ml / kg / day for 5 days before infection and 1 hour after infection.
[0163] Group 3 - Male mice (n=15) administered a combination of purified water + AMC intragastrically at a dose of 25 mg / kg in 10 ml / kg of 0.9% NaCl for 5 days before infection and intragastrically at a dose of 10 ml / kg / day 1 hour after infection.
[0164] Group 4 - AMC was administered intraperitoneally to male mice (n=15) at a dose of 25 mg / kg in 10 ml / kg of 0.9% NaCl 1 hour after infection.
[0165] Group 5 - Positive control male mice (n=15) administered gentamicin (Sigma) via intraperitoneal route at a dose of 15 mg / kg in 10 ml / kg of 0.9% NaCl.
[0166] Test Design: A model of bacterial pneumonia in neutropenic mice was established. Klebsiella Pneumonia (BAA-1705 strain with AMC resistance, 10 6 To induce neutropenia, mice were administered 150 mg / kg and 100 mg / kg cyclophosphamide by intraperitoneal route on days 4 (day -4) and 1 (day -1) prior to infection, respectively.
[0167] Bacterial burden in the lungs and body weight as general health parameters were assessed. Survival was recorded twice daily.
[0168] Statistical analysis of the data was performed using the Kruskal-Wallis test combined with post-hoc Tukey's test and Kaplan Meier curves, followed by pairwise comparisons with the log-rank test. Differences were considered statistically significant when p<0.05.
[0169] Test results: None of the test substances affected lung weight and CFU counts in infected animals. Infection-induced weight loss was observed in all test groups (Figure 7). Weight gain was observed in group 5 (gentamicin) and group 1 (AMC+medicine) from 54 hours into the follow-up period.
[0170] Mortality in all groups was recorded during the follow-up period from 48 to 54 hours (Figure 8). All animals in the control and AMC+control groups died, indicating a lack of resistance to antibiotics. Klebsiella Pneumonia Resistance to (BAA-1705) was confirmed. Gentamicin and AMC+drug treatment improved survival in mice, with 70% and 50% of animals surviving, respectively.
[0171] Conclusion: Therefore, this test is AMC-resistant. Klebsiella Pneumonia The results showed a significant antibacterial effect of the claimed drug in combination with AMC against the strain, which was comparable to that of the comparator drug gentamicin, to which this strain was resistant.
[0172] Test Number 2 Experimental Group: Group 1 - Male mice administered the claimed drug intragastrically at a dose of 20 ml / kg / day for 5 days before infection and 2 days after infection (n=5) and 1 hour after infection, AMC was administered by intraperitoneal route at a dose of 25 mg / kg in 10 ml / kg of 0.9% NaCl.
[0173] Group 2 - Control male mice that were intragastrically administered purified water at a dose of 20 ml / kg / day for 5 days before infection and 2 days after infection (n=5), and 1 hour after infection, AMC was administered by intraperitoneal route at a dose of 25 mg / kg in 10 ml / kg of 0.9% NaCl.
[0174] Test Design: Klebsiella Pneumonia (BAA-1705 strain with AMC resistance, 10 7A bacterial pneumonia model animal was established by administering 1 × 10 CFU / mouse to the lung tissues of both groups of mice 48 hours after infection. 4 CFU / ml Klebsiella Pneumonia The bacteria (5 × 10 4 CFU / well) were incubated with 2.5–1080 μg / ml AMC for 24 h at 37 °C. At the end of the experiment, the 50% inhibitory concentration (IC50) of AMC was estimated for each group by spectrophotometric colorimetry to estimate the value of 100% bacterial growth inhibition upon exposure to 1080 μg / ml AMC. Experiments were performed in duplicate. Additional experiments were performed to evaluate the effect of AMC IC50 on intact bacteria (see Figure 9).
[0175] Statistical analysis of the obtained data was performed using one-way and two-way ANOVA followed by pairwise comparisons with the log-rank test. Differences were considered statistically significant when p<0.05.
[0176] Test results: AMC showed 100% inhibitory concentration at 1080μg / ml. Klebsiella Pneumonia Resistance to (BAA-1705) was confirmed. In in vitro tests, co-administration of the claimed drug with AMC reduced the IC50 of AMC by 27%, i.e. the applied treatment reduced the AMC concentration inducing 50% bacterial growth inhibition. Analysis of the effect of the tested combinations on a constant AMC concentration of 1080 μg / ml (100% growth inhibition concentration) showed similar results: the maximum inhibitory effect of AMC was increased by 26% (Figure 9).
[0177] Conclusion: Therefore, this test is a test for AMC resistance resulting in a decrease in bacterial resistance to AMC. Klebsiella Pneumonia The results showed a significant antibacterial effect of the combination of the claimed medicine with AMC against the strains. The claimed medicine was shown to be effective against pulmonary infections.
[0178] Example 7 Anti-inflammatory activity of the claimed drug in a carrageenan-induced inflammation model in rats
[0179] The aim of this study is to evaluate the anti-inflammatory activity of the claimed drug in a carrageenan-induced inflammation model in rats in comparison with the anti-inflammatory drug indomethacin (Sigma).The drug of the invention contains equal amounts of two technical preparations obtained from serial dilutions (C12C30C50 dilutions) of a stock material of affinity-purified polyclonal antibodies: 1) an antibody against the β1 domain of major histocompatibility complex class II molecules (2.5 mg / ml) and 2) an antibody against the β2-microglobulin of major histocompatibility complex class I molecules (2.5 mg / ml).
[0180] Experimental Group: Group 1 - Male rats (n=10) administered the claimed drug intragastrically at a dose of 7.5 ml / kg / day for 5 days prior to inflammation induction (last administration - 1 hour prior to induction).
[0181] Group 2: Male rats (n=10) that received purified water intragastrically at a dose of 7.5 ml / kg / day for 5 days before inflammation induction (last administration - 1 hour before induction).
[0182] Group 3 - positive control male rats administered indomethacin intragastrically at a dose of 10 mg / kg (7.5 ml / kg / day in purified water).
[0183] Test Design: An inflammatory response was induced in animals by subplantar injection (into the plantar aponeurosis of the left hind paw) of 0.1 ml of a 1% carrageenan solution.
[0184] The severity of the inflammatory response was assessed by estimating the edema weight increase (in mg), calculated as the difference between paw weights with and without edema.
[0185] Statistical analysis of findings was performed using the Kruskal-Wallis test combined with post-hoc Tukey's test. Differences were considered statistically significant when p<0.05.
[0186] Test results: The claimed drug reduced edema weight by 39.1% and indomethacin by 57.9% compared to the control (Figure 10).
[0187] Conclusion: Thus, the claimed pharmaceutical, i.e., a composition of a technical process obtained from serial dilution of a stock material of an antibody against HLA DRB1 and a technical process obtained from serial dilution of a stock material of an antibody against β2-MG, exhibited significant anti-inflammatory activity in a carrageenan-induced inflammation model in rats by reducing paw edema weight.
[0188] Example 8 Salmonella enterica Antibacterial activity of the claimed drug against streptomycin- or nalidixic acid-resistant strains of
[0189] This is a blinded, placebo-controlled study. The objectives of this study are: Salmonella enterica The aim of the study was to evaluate the effect of the claimed drug on the antibiotic susceptibility and resistance index in experimental peritonitis (sepsis) in mice caused by serotype Typhimurium LT-2. The drug of the present invention comprises a technical preparation obtained from serial dilution of a stock material of antibodies against HLA-DRB1 (dilution of polyclonal antibodies in С12C30C50 (2mg / ml) in a ratio of 2:1:3) and a technical preparation obtained from serial dilution of a stock material of antibodies against β2-MG (dilution of polyclonal antibodies in С12C30C50 (2mg / ml) in a ratio of 2:1:3) in a volume ratio of 1:1.
[0190] Experimental Group: Group 1- Salmonella enterica (5.0 log10 CFU / animal by intraperitoneal route, streptomycin-susceptible Salmonella enterica Typhimurium LT-2 (JB270 strain) and streptomycin resistance Salmonella entericaFemale BALB / c mice (n=12) were orally administered placebo (purified water) at 1, 4, and 8 hours after infection with T. typhimurium LT-2 (1:1 combination with JB271 strain). Dose-10 ml / kg.
[0191] Group 2- Salmonella enterica (5.0 log10 CFU / animal by intraperitoneal route, streptomycin-susceptible Salmonella enterica Typhimurium LT-2 (JB270 strain) and streptomycin resistance Salmonella enterica Female BALB / c mice (n=12) were orally administered the claimed drug at 1, 4 and 8 hours after infection with T. typhimurium LT-2 (1:1 combination with JB271 strain). Dose-10 ml / kg.
[0192] Group 3- Salmonella enterica (5.0 log10 CFU / animal by intraperitoneal route, streptomycin-susceptible Salmonella enterica Typhimurium LT-2 (JB270 strain) and streptomycin resistance Salmonella enterica Female BALB / c mice (n=12) infected with 1:1 combination with Typhimurium LT-2 (strain JB271); mice from groups 1 and 2 that did not receive any agent (naive animals).
[0193] Group 4- Salmonella enterica (5.0 log10 CFU / animal via intraperitoneal route, nalidixic acid sensitive Salmonella enterica Typhimurium LT-2 (JB270 strain) and nalidixic acid resistance Salmonella enterica Female BALB / c mice (n=12) were orally administered placebo (purified water) at 1, 4, and 8 hours after infection with T. typhimurium LT-2 (1:1 combination with JB285 strain). Dose-10 ml / kg.
[0194] Group 5- Salmonella enterica (5.0 log10 CFU / animal via intraperitoneal route, nalidixic acid sensitive Salmonella enterica Typhimurium LT-2 (JB270 strain) and nalidixic acid resistance Salmonella enterica Female BALB / c mice (n=12) were orally administered the claimed drug at 1, 4 and 8 hours after infection with T. typhimurium LT-2 (1:1 combination with JB285 strain). Dose-10 ml / kg.
[0195] Group 6- Salmonella enterica (5.0 log10 CFU / animal by intraperitoneal route, streptomycin-susceptible Salmonella enterica Typhimurium LT-2 (JB270 strain) and streptomycin resistance Salmonella enterica Female BALB / c mice (n=12) infected with 1:1 combination with Typhimurium LT-2 (strain JB285); mice from groups 4 and 5 that did not receive any agent (naive animals).
[0196] Test Design: The test period was 5 days. Peritonitis (sepsis) was either sensitive or resistant to streptomycin and nalidixic acid. Salmonella enterica JB270+JB271[Strep R ] in a 1:1 ratio, or JB270+JB285[Nal R ] were intraperitoneally injected into mice at a 1:1 ratio.
[0197] Test samples were administered orally at a dose of 10 ml / kg at 1, 4, and 8 hours post-infection.
[0198] On days 2, 3, and 4 post-infection, four mice per group were euthanized by cervical dislocation and their spleens were harvested. The harvested organs were homogenized and serially diluted. 20 μl of the resulting 10-fold dilutions were then plated in triplicate on LB agar plates containing antibiotics (streptomycin at a dose of 50 μg / ml or nalidixic acid at a dose of 30 μg / ml).
[0199] After 24 hours, the number of colony forming units (CFU) per dilution was counted and JB270 / JB271 [Strep R ] or JB270 / JB285[Nal R A susceptibility-resistance index of 100 μg / g of spleen tissue was calculated for each mouse.
[0200] Statistical analysis of findings was performed using two-way repeated measures ANOVA combined with post-hoc Tukey's test. Differences were considered statistically significant when p<0.05.
[0201] Test results: Streptomycin resistance Salmonella enterica (JB271[Strep R Experiments using a 1:1 ratio of JB270 / JB271[Strep R] ratios exceeded both the baseline values of this group (66.7% and 63.6%, respectively) and those of the control group. Compared to group 1 (placebo), the values were found to increase: 75% and 72.7% on the second day of the study, 75% and 72.7% on the third day, 66.7% and 63.6% on the fourth day, and 58.3% and 54.5% on the fifth day. Compared to group 3 (untreated animals), the values were found to increase: 75% and 72.7% on the second day of the study, 83.3% and 81.8% on the third day, and 58.3% and 54.5% on the fourth and fifth days (Figure 11).
[0202] Nalidixic acid resistance Salmonella enterica (JB285[Nal R In an experiment using a 1:1 ratio of JB270 / JB285 [Nal R The ratio exceeded by 50% the value obtained for the same group on the third day of the study. Moreover, the results obtained for group 5 on the fifth day of the study were also significantly different from those of both control groups throughout the study period. Compared to group 4 (placebo), the respective values were found to increase by 70-90%, whereas the difference with group 6 (untreated animals) varied between 30-80% (Figure 12).
[0203] Conclusion: Therefore, this study Salmonella enterica The results showed a remarkable antibacterial effect of the claimed drug against the bacteria, and the bacterial resistance to the tested antibiotics streptomycin and nalidixic acid was significantly reduced (i.e., JB271[Strep R ] and JB285[Nal R ] CFU counts were reduced).
[0204] Example 9 Clostridium perfringens Efficacy of drugs in mice infected with (ATCC 13124)
[0205] This is a blinded, placebo-controlled study. The purpose of this study is to Clostridium perfringens The object of the present invention is to evaluate the antibacterial activity of the claimed drug in experimental infection of mice with . The drug of the present invention comprises a technical preparation obtained from serial dilution of a stock material of antibodies against HLA-DRB1 (dilution of monoclonal antibodies in С12D50D200 (1.5 mg / ml) in the ratio of 1:2:3) and a technical preparation obtained from serial dilution of a stock material of antibodies against β2-MG (dilution of polyclonal antibodies in С12D50D200 (1.5 mg / ml) in the ratio of 2:1:3) in a volume ratio of 2:1.
[0206] Experimental Group: Group 1- Clostridium perfringens ATCC 13124 (intraperitoneal route, 10 10 CFU / animal) Female outbred Swiss Webster mice (n=20) orally administered placebo (purified water) for 5 days before infection, 2 hours and 8 hours after infection. Dose-10 ml / kg.
[0207] Group 2- Clostridium perfringens ATCC 13124 (intraperitoneal route, 10 10 CFU / animal) Female outbred Swiss Webster mice (n=20) orally administered the claimed drug for 5 days before infection, 2 hours and 8 hours after infection. Dose-10 ml / kg.
[0208] Group 3- Clostridium perfringens ATCC 13124 (intraperitoneal route, 10 10 Female outbred Swiss Webster mice (n=20) administered tetracycline by intraperitoneal route at a dose of 21 mg / kg (CFU / animal) 30 min, 4 h, and 8 h postinfection.
[0209] Group 4- Clostridium perfringens ATCC 13124 (intraperitoneal route, 10 10 Female outbred Swiss Webster mice (n=20) administered cefoxitin by intraperitoneal route at a dose of 160 mg / kg (CFU / animal) 30 min, 4 h, and 8 h postinfection.
[0210] Group 5- Clostridium perfringens ATCC 13124 (intraperitoneal route, 10 10 CFU / animal) female outbred Swiss Webster mice (n=20) administered deionized water by intraperitoneal route in a volume of 0.1 ml / kg at 30 min, 4 h, and 8 h postinfection.
[0211] Test Design: The experimental infection of mice was carried out over 8 days. Clostridium perfringens (ATCC 13124), 10 10 The challenge was carried out by intraperitoneal injection at a dose of 100 CFU / animal.
[0212] Test samples were administered orally at a dose of 10 ml / kg for 5 days before infection, and at 2 and 8 hours after infection.Comparative drugs - cefoxitin at 21 mg / kg and tetracycline at 160 mg / kg - and their controls (deionized water, 0.1 ml / kg) were injected via the intraperitoneal route at 30 minutes, 4 hours and 8 hours after infection.
[0213] Animal survival was estimated for each group at 12, 24, 48, and 72 hours post-infection.
[0214] Statistical analysis of the findings was performed using Kaplan Meier curves followed by pairwise comparisons with the log-rank test. Differences were considered statistically significant when p<0.05.
[0215] Test results: The highest mortality rate among the infected mice was observed in both control groups, with only 5% of the mice surviving in group 1 (purified water) and 100% of the mice in group 5 (deionized water) dying 24 hours after the animals were infected with the bacteria. Therapeutic and prophylactic administration of the claimed drug (5 days before infection and 2 and 8 hours after infection) significantly increased the survival rate of the animals. In this group, 85% of the animals survived 12 hours after infection; 55% survived 24 hours and 40% survived 48 hours and beyond. In this group, 85% of the animals survived 12 hours after infection; 55% survived 24 hours and 40% survived 48 hours and beyond. In the comparative drug groups, i.e. tetracycline and cefoxitin, the number of animals surviving 12, 24, 48 and 72 hours after infection was 95%, 85%, 80%, 80% (no deaths observed at the last measurement) and 65%, 55%, 15%, 15% (no deaths observed at the last measurement), respectively. It should be noted that the antibacterial effect of the claimed drug was significantly stronger than that obtained in the cefoxitin group. Nevertheless, both drugs were less active than tetracycline (Figure 13).
[0216] Conclusion: Therefore, this study Clostridium perfringens (ATCC 13124) and resulted in a significant increase in survival rate as compared to the two control groups (groups 1 and 5) and the comparator drug cefoxitin.
[0217] Example 10 Chlamydophila pneumonia Antibacterial activity of the claimed drug against strain CM1
[0218] This is a blinded, placebo-controlled study. The objectives of this study are: Chlamydophila pneumonia The aim of the study was to evaluate the antibacterial activity of the claimed drug in experimental infection of mice with strain CM1 (model of pulmonary infection).The drug of the invention comprises a technical preparation obtained from serial dilution of a stock material of antibodies against HLA-DRB1 (dilution of polyclonal antibodies in C20C50C200 in a ratio of 2:1:3 (1.5 mg / ml)) and a technical preparation obtained from serial dilution of a stock material of antibodies against β2-MG (dilution of polyclonal antibodies in C20C50C200 in a ratio of 2:1:3 (3 mg / ml)) in a volume ratio of 1:2.
[0219] Experimental Group: Group 1- Chlamydophila pneumonia CM1 strain (by intratracheal route, 1.5 * 10 6 Male C57BL / 6J mice (n=21) were orally administered placebo (purified water) for 3 days before and 2, 24, 48, and 72 hours after injection of IFU / animal (IFU-inclusion body forming units). Dose-10 ml / kg.
[0220] Group 2- Chlamydophila pneumonia CM1 strain (by intratracheal route, 1.5 * 10 6 Male C57BL / 6J mice (n=21) were orally administered the claimed drug for 3 days before and 2, 24, 48 and 72 hours after injection of 100 mg / kg IFU / animal. Dosage-10 ml / kg.
[0221] Group 3- Chlamydophila pneumonia CM1 strain (by intratracheal route, 1.5 * 10 6 Male C57BL / 6J mice (n=21) were administered azithromycin subcutaneously 30 min after injection of 100 mg / kg IFU / animal and then every 24 h (days 2, 3, and 4).
[0222] Group 4 - Intact male C57BL / 6J mice (n=5) [background control for estimation of cytokine levels].
[0223] Test Design: The study period was 15 days. The lung infection model was performed in mice at 1.5 * 10 6 Dose of IFU / mouse: Chlamydophila pneumonia The induction was by intratracheal administration of (CM1).
[0224] In groups 1 and 2, the test samples were administered orally at a dose of 10 ml / kg for 3 days before infection and 2, 24, 48, and 72 hours after bacterial injection. The comparative drug azithromycin (group 3) was administered subcutaneously at a dose of 10 mg / kg 30 minutes after infection and then every 24 hours (days 2, 3, and 4).
[0225] The survival rate of the animals was evaluated on days 3, 6, and 12 after infection. On the same days, four mice from each of the three groups, i.e., groups 1 to 3, were sacrificed by cervical dislocation and their lungs were harvested. The harvested organs were homogenized and the resulting homogenates were used to perform Chlamydophila pneumonia (CM1) bacterial load and cytokine levels (IL-1β, IL-6, and TNF-α) were measured.
[0226] Intact animals, whose biological specimens (lung tissue homogenates) were used for measuring cytokine levels to obtain background values, were sacrificed on day 3 postinfection of mice in groups 1–3.
[0227] To estimate bacterial load, 20 μl samples of lung homogenates were plated in triplicate on RPMI1640 medium containing 1 mg / ml cycloheximide and HEp2 cells and incubated for 72 h. Cells were then washed with PBS, blocked with methanol, and stained with a FITC-conjugated monoclonal antibody against a genus-specific antigen of Chlamydia (Pathfinder Chlamydia Culture Confirmation System; BIO-RAD, Hercules, USA). Preparations were examined using a fluorescent microscope, and infected cells were counted.
[0228] Cytokine levels were measured using an ELISA test system from Bender MedSystems (USA) according to the manufacturer's instructions.
[0229] Statistical analysis of findings was performed using the Kruskal-Wallis test combined with post-hoc Tukey's test and Kaplan Meier curves followed by pairwise comparisons with the log-rank test. Differences were considered statistically significant when p<0.05.
[0230] Test results: The intact group showed 100% animal survival.
[0231] The highest mortality rate of infected mice was observed in the control group: on the third day of the study, 53% of the mice of group 1 (purified water as placebo) survived after bacterial inoculation, whereas from the sixth day onwards, only 24% of the mice did so. Therapeutic and prophylactic administration of the claimed drug (group 2) (for three days before infection and for 2, 24, 48 and 72 hours after bacterial inoculation) significantly increased the survival rate of the animals. On the third day after infection, 72% of the animals survived in this group, whereas from the sixth day onwards, 62% of the mice survived. The highest survival rate (81%) was observed in the animals treated with the comparative drug azithromycin (group 3), where death was first recorded on the third day after infection, with a mortality rate of 19% (Figure 14).
[0232] Chlamydophila pneumonia Bacterial load, determined from the number of infected HEp2 cells after exposure to lung tissue homogenates from mice infected with (CM1), showed a linear reduction in the test parameters in response to the claimed drug treatment compared to placebo, with infected cell counts in group 2 (drug) of 67%, 58%, and 21%, respectively, on days 3, 6, and 12 post-infection. A more pronounced reduction in bacterial load was observed with the comparator drug azithromycin (group 3), up to 15%, 17%, and 5%, respectively, on days 3, 6, and 12 post-infection (Figure 15).
[0233] Testing of the immunotropic activity of the claimed drug showed that both IL-1β and IL-6 levels were significantly and linearly decreased in response to the therapeutic and prophylactic course of the drug (group 2) compared to the control. On days 3, 6, and 12 after infection, IL-1β concentrations were 55%, 21%, and 20% of the control level (group 1, purified water), and IL6 concentrations were 57%, 34%, and 27%, respectively. In group 3 (comparison drug azithromycin), both interleukin levels showed a more pronounced linear decrease, as did the bacterial load values (IL-1β: decreased to 17%, 7%, and 6% of the control level on days 3, 6, and 12 after infection, respectively; IL-6: decreased to 15%, 8%, and 5%, respectively) (Figures 16, 17).
[0234] TNF-α levels in lung tissue of mice showed no changes in any of the groups, suggesting that no changes in the concentration of this cytokine and no biological significance were observed in the experimental model of induced pulmonary infection (Figure 18).
[0235] Conclusion: therefore, Chlamydophila pneumonia Studies on a model of pulmonary infection caused by the CM1 strain showed a significant and concomitant antibacterial and immunotropic action of the claimed drug. The exerted activity resulted in a more than 2.5-fold increase in the survival rate of the animals by the end of the study, a 79% reduction in the bacterial load in the lungs, and also in a reduction in the levels of pro-inflammatory cytokines (IL-1β reduced by 80% and IL-6 reduced by 73%).
[0236] Example 11 Klebsiella pneumoniae Antibacterial activity of the claimed drug against strain 8637
[0237] This is a blinded, placebo-controlled study. The objectives of this study are: Klebsiella pneumoniae The aim of the study was to evaluate the antibacterial activity of the claimed drug in experimental infection of immunodeficient mice (neutropenic pulmonary infection model) with strain 8637. The drug of the present invention comprises a technical preparation obtained from serial dilution of a stock material of antibodies against HLA-DRB1 (dilution in C30C200 (3 mg / ml) of monoclonal antibodies in a ratio of 2:3) and a technical preparation obtained from serial dilution of a stock material of antibodies against β2-MG (dilution in C30C200 (3 mg / ml) of polyclonal antibodies in a ratio of 3:1) in a volume ratio of 1:1.
[0238] Experimental Group: Group 1- Klebsiella pneumoniae 8637 strains (via intranasal route, 2 * 10 7 Female ICR mice (n=20) were orally administered placebo (purified water) at 4, 6, 8, 24 and 48 hours after infection with 100 μg / animal CFU. Dose-10 ml / kg.
[0239] Group 2- Klebsiella pneumoniae 8637 strains (via intranasal route, 2 * 10 7 Female ICR mice (n=20) were orally administered the claimed drug at 4, 6, 8, 24 and 48 hours after infection with 1000 mg / kg of IgG1 (CFU / animal). Dose-10 ml / kg.
[0240] Group 3- Klebsiella pneumoniae 8637 strains (via intranasal route, 2 * 10 7 Female ICR mice (n=20) administered the comparator drug imipenem by intraperitoneal route at 4, 24, and 48 hours post-infection with 100 μg / animal.
[0241] Test Design: The test period was 9 days. * 10 7 In terms of CFU / animal dose, Klebsiella pneumoniae (strain 8637) was intranasally inoculated into immunodeficient mice. To induce neutropenia (immunosuppression), animals were administered cyclophosphamide by intraperitoneal route at a dose of 200 mg / kg 4 days (day -4) prior to infection.
[0242] In groups 1 and 2, the test samples were administered orally at a dose of 10 ml / kg during the treatment regimen, i.e., 4, 6, 8, 24, and 48 hours after bacterial inoculation. The comparative drug imipenem (group 3) was administered intraperitoneally at a dose of 2 mg / kg, 4, 24, and 48 hours after infection.
[0243] Klebsiella pneumoniae The survival rate of the animals was estimated for 5 days after infection with (strain 8637). At the end of the experiment, i.e., 5 days after infection, 5 mice per group were sacrificed and blood, lungs, liver, spleen, and kidneys were removed to determine the CFU counts. Isolated organs were homogenized and serially diluted. 200 μl of 10-fold dilutions of all tissue samples were plated in triplicate on Mueller-Hinton agar and incubated for 24 h.
[0244] Statistical analysis of findings was performed using one-way ANOVA combined with post-hoc Tukey's test and by comparing survival curves using the log-rank test with Benjamini-Hochberg correction for multiple testing. Differences were considered statistically significant when p<0.05.
[0245] Test results: The highest mortality rate of infected mice was observed in the control group, where 55% of the mice in group 1 (purified water as placebo) survived on the first day of the study, 2, 3, 4 and later days after bacterial inoculation, with 45%, 20%, and 15% of the mice surviving, respectively. Treatment with the claimed drug (group 2) (4, 6, 8, 24, and 48 hours after bacterial inoculation) significantly increased the survival rate of the animals. On the first day after infection, 85% of the animals survived in this group, and on the second, third, fourth, and later days, 70%, 60%, and 45% of the mice survived, respectively. The highest survival rate was observed in animals administered the comparative drug imipenem (group 3), with 85% surviving on the first day after infection, 70% on the second day, and 50% surviving from the third day after infection (Figure 19).
[0246] Klebsiella pneumoniae Evaluation of the bacterial burden in blood, lungs, liver, spleen, and kidneys of immunodeficient mice infected with (strain 8637) showed that the number of CFUs was reduced in all tissues in response to the claimed pharmaceutical treatment compared to the control (placebo): 68% in blood, 56% in lungs, 36% in liver, 33% in spleen, and 44% in kidneys. A similar effect was observed for the comparator drug imipenem (group 3), with a 67%, 48%, 40%, 45%, and 61% reduction in the bacterial burden in blood, lungs, liver, spleen, and kidneys, respectively (Figure 20).
[0247] Conclusion: Therefore, cyclophosphamide and Klebsiella pneumoniae Tests performed on a pulmonary infection model in immunodeficient mice induced by administration of B. cerevisiae (strain 8637) showed a significant antibacterial activity of the claimed drug: the observed activity was accompanied by a 30% increase in survival rate compared to placebo and at least a third reduction in bacterial load in blood, lungs, liver, spleen and kidneys by the end of the study.
[0248] Example 12 Antiviral activity of the claimed drug against a model of lethal influenza infection caused by influenza A / California / 07 / 09(H1N1)pdm09 strain in white mice
[0249] This is a blinded, placebo-controlled study. The purpose of this study is to evaluate Tamiflu in vivo at an effective dose against the influenza A / California / 07 / 09(H1N1)pdm09 strain. TM The object of the present invention is to investigate the antiviral activity of the claimed drug in comparison with (oseltamivir). The drug of the present invention comprises technical preparations obtained from serial dilutions of stock materials of a) antibodies against HLA-DRB1 (diluted with C12C30C50 in a ratio of 1:3:1), b) antibodies against β2-microglobulin (diluted with C12C30C50 in a ratio of 1:3:1), c) antibodies against interferon gamma (diluted with C12C30C50 in a ratio of 1:3:1) and d) antibodies against CD4 (diluted with C12C30C50 in a ratio of 1:3:1) in a volume ratio of 1:1:1:1. A) Technical treatment (2.5 mg / ml) resulting from serial dilutions of a stock material of polyclonal antibodies against the β1 domain of major histocompatibility complex class II molecules (HLA-DRB1) obtained by combining three different serial dilutions of a stock (matrix) solution of polyclonal antibodies against HLA-DRB1 in hydroalcoholic solvent. The following dilutions were mixed in a ratio of 1:3:1: 1) While shaking each dilution, 12 A 2-fold diluted stock (matrix) solution (equivalent to a C12 dilution). 2) While shaking each dilution, 30 A 2-fold diluted stock (matrix) solution (equivalent to a C30 dilution). 3) While shaking each dilution, 50 A 2-fold diluted stock (matrix) solution (equivalent to a C50 dilution). B) Technical treatment (1.0 mg / ml) resulting from serial dilutions of a stock material of a monoclonal antibody against β2-microglobulin (β2-MG) obtained by combining three different serial dilutions of a stock (matrix) solution of a polyclonal antibody against β2-MG in aqueous solvent. The following dilutions were mixed in a volume ratio of 1:3:1: 1) While shaking each dilution, 12A 2-fold diluted stock (matrix) solution (equivalent to a C12 dilution). 2) While shaking each dilution, 30 A 2-fold diluted stock (matrix) solution (equivalent to a C30 dilution). 3) While shaking each dilution, 50 A 2-fold diluted stock (matrix) solution (equivalent to a C50 dilution). C) Technical treatment (2.5 mg / ml) resulting from serial dilutions of a stock material of a polyclonal antibody against interferon gamma (IFN-γ) obtained by combining three different serial dilutions of a stock (matrix) solution of a polyclonal antibody against IFN-γ in hydroalcoholic solvent. The following dilutions were mixed in a ratio of 1:3:1: 1) While shaking each dilution, 12 A 2-fold diluted stock (matrix) solution (equivalent to a C12 dilution). 2) While shaking each dilution, 30 A 2-fold diluted stock (matrix) solution (equivalent to a C30 dilution). 3) While shaking each dilution, 50 A 2-fold diluted stock (matrix) solution (equivalent to a C50 dilution). D) Technical treatment (1.0 mg / ml) resulting from a serial dilution of a stock material of a polyclonal antibody against CD4, obtained by combining three different serial dilutions of a stock (matrix) solution of a polyclonal antibody against CD4 in hydroalcoholic solvent. The following dilutions were mixed in a ratio of 1:3:1: 1) While shaking each dilution, 12 A 2-fold diluted stock (matrix) solution (equivalent to a C12 dilution). 2) While shaking each dilution, 30 A 2-fold diluted stock (matrix) solution (equivalent to a C30 dilution). 3) While shaking each dilution, 50 A 2-fold diluted stock (matrix) solution (equivalent to a C50 dilution).
[0250] Experimental Group: Group 1 - animals (n=30) that received placebo throughout the experiment (negative control ("virus control")).
[0251] Group 2 - 5 days after infection, comparison drug Tamiflu TM (oseltamivir) followed by open-label placebo (n=30) (positive control comparison drug).
[0252] Group 3 - Mice (n=30) that received the claimed drug throughout the experiment.
[0253] Group 4 - mice (n=30) that received an activation enhancing form of antibody to interferon gamma throughout the experiment.
[0254] Group 5 - mice that received an activation enhancing form of an antibody against CD4 throughout the experiment (n=30).
[0255] Group 6 - mice (n=30) that received an activation enhancing form of antibody against HLA-DRB1 throughout the experiment.
[0256] Group 7 - mice that received an activation enhancing form of antibody against β2-microglobulin throughout the experiment (n=30).
[0257] Test Design: The animals were orally administered the claimed drug in a volume of 0.4 ml / mouse twice a day, in the morning and in the evening, at 10 am and 5 pm (0.8 ml / mouse / day) for 5 days before infection, 4 hours before infection, 4 hours after infection, and 14 days after infection (total administration time of the test substance was 20 days) until the end of the experiment [“Guidelines on non-clinical studies of pharmaceutical products” edited by AN Mironov (Moscow, 2012)].
[0258] The virus was inoculated into the animals via the intranasal route at a volume of 0.05 ml / mouse (2.5×103TCID50, 5LD50) [He B, Fu Y, Xia S, et al. Intranasal application of polyethyleneimine suppresses influenza virus infection in mice. Emerging Microbes & Infections. 2016;5(4):e41-. doi:10.1038 / emi.2016.64.].
[0259] Comparison drug: Tamiflu TM (Oseltamivir) was administered orally by gavage at a dose of 15 mg / kg in a volume of 0.4 ml / mouse twice a day at 10 am and 5 pm for 5 days after infection (30 mg / mouse / day). Administration began 1 hour before infection [Oseltamivir in influenza A / H1N1 / / Journal of Antimicrobial Chemotherapy, 2005, 55, p.5-21]. In this group, mice were administered distilled water in a volume of 0.4 ml / mouse twice a day (0.8 ml / mouse / day) for 5 days before infection and from day 6 to 14 after infection until the end of the follow-up period. Negative controls were also administered placebo in a volume of 0.4 ml / mouse twice a day (0.8 ml / mouse / day) throughout the follow-up period.
[0260] All mice were examined for zootechnical parameters (live weight, survival rate, mean life expectancy (MLE), protection index) and subjected to virological testing.
[0261] Test results: The raw data on the activity of the claimed drug, showing mortality, mean life expectancy (MLE) and protection index, are summarized in Table 1. The follow-up period was 14 days after infection of the animals. Mortality was recorded daily in the control and test groups. Based on the data obtained, the following parameters were calculated:
[0262] - Mortality - the number of dead animals over 14 days relative to the total number of infected animals per group: M (% mortality) = M / Nt
[0263] Protection Index - the difference in % mortality between the control and test groups relative to the % mortality of the control group: PI = ((Mc-Me) / Mc) x 100%
[0264] Mean animal lifespan over 14 days of the follow-up period: MDD=(ΣN×D) / Nt, where M-1 is the number of dead animals over 14 days per group, Mc and Me- the mortality rates in the control (virus control) and test groups respectively, ND is the number of animals surviving days, Nt-1 is the total number of infected animals per group. Table 4. [Table 4]
[0265] As can be seen from the data obtained, infection of mice with influenza A / California / 097 / 09(H1N1)pdm09 activated pathological processes and led to 75% animal mortality at an average of 8.5 days after infection. Administration of the claimed drug reduced the mortality rate to 25% (protection index 64.2%). The MLE value for this group was 8.9 days.
[0266] When analyzing body weight changes, only data from animals included in the mortality analysis (14 days post-infection) were examined. Table 5. Body weights of experimental animals expressed as M ± SD [Table 5]
[0267] Viral titers were determined in lung tissue 5 days after infection of animals (n=10). The mean infectious titers of influenza virus in the lungs of animals in each group are shown in Table 6. Table 6. [Table 6]
[0268] According to the Guidelines on non-clinical studies of pharmaceutical products / Ed. by AN Mironov. - Moscow: ZAO Grif and Co. - 2012. - Part 1. - 944 p., a decrease in the viral titer of 1.75 lg or more in the treated animal group indicates inhibition of its replication. In this test, the claimed drug reduced the viral titer to 2.4 lgTCID 50 It was lowered.
[0269] Conclusion: The highest activity in terms of reducing mortality was observed for the claimed drug (PI=64.2), whose combined efficacy was higher than that of each component alone. In addition, the drug of the present invention showed a significant antiviral effect, reducing the viral titer by 2.4 lgTCID 50 It was lowered.
[0270] Example 13 In vivo influenza A / New Jersey / 8 / 76 (H1N1) virus and Streptococcus pneumoniae ( S.pneumoniae Testing the antibacterial activity of drugs 1 and 2 after successive infection of animals with
[0271] The purpose of this study was to determine the severity of influenza A / New Jersey / 8 / 76 (H1N1) virus infection in animals 7 days after infection. S.pneumoniae The objective of the present invention is to comparatively evaluate the antibacterial effects of drugs 1 and 2 against pneumococcal infections caused by Streptococcus pneumoniae. Drug 1 contains an antibody against human IFN-γ, an antibody against histamine, and an antibody against CD4 at 100 12 , 100 30 , 100 50The drug 2 of the invention is a mixture of three hydroalcoholic dilutions diluted 1:1:1 in a volume ratio of 1:1:1. The drug 2 of the invention comprises technical preparations obtained from serial dilutions of the stock substances of a) antibodies against HLA-DRB1 (polyclonal antibodies diluted at C12C30C50 (2 mg / ml) in a ratio of 1:1:1), b) antibodies against β2-microglobulin (polyclonal antibodies diluted at C12C30C50 (2 mg / ml) in a ratio of 1:1:1), c) antibodies against interferon-gamma (monoclonal antibodies diluted at C12C30C50 (3 mg / ml) in a ratio of 1:1:1) and d) antibodies against CD4 (monoclonal antibodies diluted at C12C30C50 (3 mg / ml) in a ratio of 1:1:1).
[0272] Experimental Group: Group 1 - Female mice (n=15) administered Drug 1 intragastrically at a total dose of 20 ml / kg / day (twice a day at approximately 0.2 ml / mouse at 2-hour intervals) for 5 days prior to viral infection (day 0) and intragastrically administered 2 hours prior to infection.
[0273] Group 2 - Female mice (n=15) administered Drug 2 intragastrically at a total dose of 20 ml / kg / day (twice a day at approximately 0.2 ml / mouse at 2-hour intervals) for 5 days prior to viral infection (day 0) and 2 hours prior to infection.
[0274] Group 3 - Control female mice (n=15) that were intragastrically administered purified water daily at a total dose of 20 ml / kg / day (approximately 0.2 ml / mouse twice a day at 2-hour intervals) for 5 days prior to virus infection (day 0) and intragastrically administered 2 hours prior to infection.
[0275] Infected with group 4-A / New Jersey / 8 / 76 (H1N1) and 7 days later, S.pneumoniae Untreated control female mice infected with . This control allows for the placebo effect in group 2 (n=15).
[0276] Group 5- S.pneumoniae Model control female mice infected with IgG only. This control allows showing the effect of prior virus infection on total CFU numbers (n=15).
[0277] Test Design: Animals were inoculated with influenza A / New Jersey / 8 / 76 (H1N1) virus at 1 × 10 6 TCID 50 The mice were infected intranasally at a dose of 1 x 10 / mouse, and then intratracheally on day 7 post-viral infection. 6 At CFU S.pneumoniae infected. S.pneumoniae At 24, 48, and 120 hours post-inoculation, five mice per group were sacrificed and their lungs were isolated to assess bacterial load. The harvested lungs were homogenized in sterile phosphate buffer and serially diluted. The dilutions were then plated on solid medium plates and the grown colonies were counted. The results were expressed as CFU / g lung.
[0278] Test results: In this study, 7 days after animals were infected with influenza A / New Jersey / 8 / 76 (H1N1) virus, S.pneumoniae The antibacterial activity of Drug 1 and Drug 2 against pneumococcal infection caused by Streptococcus pneumoniae was investigated. The efficacy of Drug 1 and Drug 2 against each other in this experimental model was also compared.
[0279] S.pneumoniae 24 hours after infection, S.pneumoniae The highest CFU counts were in the untreated control group (Influenza A / New Jersey / 8 / 76 (H1N1) virus and S.pneumoniae Mice infected with influenza A / New Jersey / 8 / 76 (H1N1) virus and naïve animals (infected with influenza A / New Jersey / 8 / 76 (H1N1) virus and naïve animals) and controls (infected with influenza A / New Jersey / 8 / 76 (H1N1) virus and naïve animals). S.pneumoniae By that time, the bacterial burden in the lungs of mice infected with the virus and bacteria had been significantly reduced by 2-fold and 6-fold by Drug 1 and Drug 2, respectively, compared to controls (Group 3), with Drug 2 being 3-fold more effective than Drug 1.
[0280] S.pneumoniae 48 hours after infection, S.pneumoniae The highest CFU counts were still in the untreated control and control groups. However, the absolute CFU counts in these groups had dropped by more than five-fold. By that time, the antibacterial potency of Drug 1 was twice that of the control values (Groups 3 and 4), but the lung bacterial burden in mice treated with Drug 2 (Group 2) was 24.4% of the control value (Group 3) and 26.7% of the untreated control value (Group 4). No statistically significant differences were observed between the Drug 1 and Drug 2 groups.
[0281] S.pneumoniae Only 120 hours after infection of mice with , were isolated CFUs seen in all groups.
[0282] Conclusion: Antibacterial activity tests of Drug 1 and Drug 2 showed that each drug exerted significant antibacterial activity. Comparative analysis of their specific activities showed that the claimed drug of the present invention (Drug 2) had a more significant effect than Drug 1.
[0283] Example 14 Influenza H1N1 / A California 04 / 2009 virus and Staphylococcus aureus Efficacy of the claimed drug in experimental viral / bacterial pneumonia caused by (1986 strain)
[0284] The purpose of this study is to identify the influenza H1N1 / A California 04 / 2009 virus and Staphylococcus aureus The aim of the present invention is to investigate the therapeutic activity of the claimed drug in experimental viral / bacterial pneumonia caused by HLA-DRB1 (1986 strain). The drug of the present invention contains equal amounts of four technical preparations obtained by serial dilution (C12C30C50 dilutions) of affinity purified polyclonal antibody stock materials, namely: 1) antibodies against major histocompatibility complex class II molecules (HLA-DRB1) (2.5 mg / ml), 2) antibodies against major histocompatibility complex class I molecules β2-microglobulin (2.5 mg / ml), 3) antibodies against human interferon gamma (2.5 mg / ml), and 4) antibodies against CD4 (2.5 mg / ml).
[0285] Experimental Group: Group 1 - Mice (n=10) that were intragastrically administered the claimed drug at a dose of 20 ml / kg / day for 3 days before virus infection and 5 days after virus infection.
[0286] Group 2 - mice intragastrically administered purified water for 3 days before virus infection and for 5 days after virus infection (at a dose of 20 ml / kg / day, n=10).
[0287] Group 3 - positive control 1, mice (n=10) administered oseltamivir (Tamiflu®, Hoffmann-La Roche, 10 mg / kg / day) by intraperitoneal route 4 hours before and 4 hours after viral infection, and then twice daily for 5 days.
[0288] Group 4 - positive control 2, mice (n=10) administered cefuroxime (Zinacef®, GlaxoSmithKline) subcutaneously at a dose of 20 mg / kg for 3 days after bacterial infection (or 4 days after viral infection).
[0289] Group 5 - Negative control, untreated mice infected with influenza virus and bacteria at the same time points as the other groups (n=10).
[0290] Test Design: Secondary viral / bacterial pneumonia, influenza H1N1 / A California 04 / 2009 virus, 10 4 / 5TCID 50 / 0.1ml dose, and Staphylococcus aureus (1986 stocks) 2 x 10 7 Animals were challenged by intranasal inoculation with 1000 CFU / ml of IgG. Staphylococcus aureus (1986) was administered 5 days after influenza virus infection. Two days later, the lungs of the animals (n = 3 per group) were homogenized and examined for bacterial load and virus titer. For the remaining mice, body weight was measured daily as a parameter of general health, and survival was recorded.
[0291] Statistical analysis: Statistical analysis of findings was performed using a linear mixed model with group as factor, day as covariate with cubic splines, and subject ID as random effect (between-group comparisons were performed for each day using post-hoc Tukey's test); Kaplan-Meier curves were used followed by log-rank tests with Benjamini-Hochberg correction for multiple testing; and Kruskal-Wallis tests combined with post-hoc Dunn's tests corrected by the Benjamini-Hochberg method. Differences were considered statistically significant when p<0.05.
[0292] Test results: The claimed drug reduced the mortality rate of animals with experimental secondary (viral / bacterial) pneumonia by 40% (vs. control (group 2)), similar to the effect of the comparator drug cefuroxime (group 4) (Figure 22).
[0293] The pharmaceutical agent of the present invention, like the comparative drug oseltamivir, reduced the pulmonary viral titer by more than 15% compared to the negative control group.
[0294] No statistically significant differences were observed in the bacterial load or body weight of the experimental mice.
[0295] Conclusion: Thus, the claimed drug has demonstrated therapeutic efficacy in experimental secondary viral / bacterial pneumonia by increasing the survival rate of infected animals and reducing viral multiplication in the lungs.
[0296] Example 15 Assessment of in vivo activity against respiratory syncytial virus
[0297] The purpose of this study is to evaluate the antiviral activity of the claimed drug against respiratory syncytial virus (RSV, strain A2). The drug of the present invention contains equal amounts of four technical preparations obtained by serial dilution (C12C30C50 dilution) of each of the following affinity purified polyclonal antibody stock materials: 1) antibodies against major histocompatibility complex class II molecules (HLA-DRB1) (2.5 mg / ml), 2) antibodies against major histocompatibility complex class I molecules beta2-microglobulin (2.5 mg / ml), 3) antibodies against human interferon gamma (2.5 mg / ml) and 4) antibodies against CD4 (2.5 mg / ml).
[0298] Experimental Group: Group 1 - Mice that received intragastric administration of the claimed drug at a dose of 20 ml / kg / day for 5 days prior to infection including 2 hours prior to infection and for 4 days thereafter (twice a day, approximately 0.2 ml / mouse at 2 hour intervals, n=10).
[0299] Group 2 - Mice that were administered intragastrically as monotherapy a dilution of the claimed drug (Anaferon for Children), i.e., an antibody against interferon gamma, in a dose of 20 ml (twice a day, 2 hour intervals, approximately 0.2 ml / mouse, n=10) for 5 days prior to infection, including 2 hours prior to infection, and for 4 days thereafter.
[0300] Group 3 - control mice that received purified water intragastrically at a dose of 20 ml / kg / day for 5 days before infection, including 2 hours before infection, and for 4 days thereafter (approximately 0.2 ml / mouse, twice a day at 2-hour intervals, n = 10).
[0301] Group 4 - RSV model control (n=10); mice were infected with RSV A2 at the same time points as mice in groups 1, 2, and 3.
[0302] Group 5 - RSV+UV model control (n=10); mice infected with UV-inactivated RSV A2 at the same time points as mice in groups 1, 2, and 3. UV inactivation was performed beforehand by exposing RSV to UV light for 20 minutes. Inactivated virus is a suitable negative control since it does not cause respiratory tract infection, but virion components present in the inactivated virus material may affect parameters of the animal's immune system. This control allows to show the effect of the virus on the animal's respiratory tract, which is precisely achieved by its replication.
[0303] Group 6 - intact control mice (n=10) that were not infected with the virus and were untreated.
[0304] Test Design: 5 groups of animals, 5 × 10 6 TCID 50 Animals were infected with the RSV A2 strain (RSV A2) by the intraperitoneal route at a dose of 100 mg / mouse. On the fifth day of the experiment, the bronchial hyperresponsiveness of the animals (as RSV A2 affects the airways by causing inflammation) was estimated by non-invasive plethysmography using equipment from Buxco Electronics, Wilmington, North Carolina. After adjustment and calibration of the equipment, different groups of mice were placed in a dual-chamber plethysmograph (plastic box) consisting of a nasal and a thoracic chamber separated by a collar as a partition to restrain the animals in the plethysmograph (chamber). They were inoculated with 10 μl of methacholine solutions of increasing concentrations of 0, 6.25, 12.5, and 25 mg / ml for 3 min.
[0305] At day 6 post-infection, lung viral loads were measured in all animals by real-time PCR. Harvested lung tissues were homogenized in RLT buffer (Qiagen) and common RNA was isolated using a commercial RNasy mini kit (Qiagen) according to the manufacturer's recommendations. In addition, common RNA was used as a template to synthesize cDNA using the OT-1 kit (Syntol) according to the manufacturer's recommendations. Complementary DNA (cDNA) was used in real-time PCR to quantify viral RNA. Real-time PCR techniques were performed using Syntol commercial reagent kits, specific primer kits, and the IQ5 detection system (BioRad) according to the manufacturer's recommendations.
[0306] Statistical analysis: Statistical analysis of findings was performed using two-way ANOVA, pairwise comparisons were performed by least squares, and multiplicity control was performed by simulation using the SAS PROC MIXED procedure. For RNA data, multiplicity control was performed using Dunnett's test (recorded values were first calculated). Differences were considered statistically significant when p<0.05.
[0307] Test results: The highest bronchial hyperresponsiveness was observed in mice from the control group (group 3) administered purified water. In mice treated only with the components of the claimed drug (group 2), bronchial hyperresponsiveness was intermediate and statistically different from the control. The lowest increase in bronchial resistance was recorded after the course of treatment with the claimed drug (Figure 23).
[0308] The highest concentration of viral RNA was found in samples from mice in the RSV group (group 4). UV inactivation of the virus significantly reduced the viral RNA count (up to 10-fold), but viral RNA was still detectable. This was due to the presence of a significant amount of genomic RNA in the UV-inactivated virus samples detected by quantitative PCR. The significant difference in viral RNA counts in the lungs of mice in the RSV (group 4) and RSV+UV (group 5) groups indicated that the inactivated virus was able to replicate in the airways, which demonstrated the suitability of the selected experimental model.
[0309] A statistically significant reduction in viral RNA load was recorded in samples obtained from animals in groups 1 (claimed medicine) and 2 (monotherapy with the claimed medicinal ingredient) (Group 4) compared to the control group (Group 3) and the RSV group (Group 3) (Figure 24). In the claimed medicine group, viral RNA counts were one-fourth lower than in the ingredient-only group.
[0310] Conclusion: The antiviral activity test of the claimed drug on an in vivo mouse model of RSV infection showed that the drug of the present invention reduced bronchial hypersensitivity and viral RNA load in the lungs, thus confirming the significant antiviral effect of the claimed drug on RSV (A2 strain).
[0311] Example 16 Rat Pseudomonas aeruginosa (RP73) Efficacy of medicines in infectious diseases
[0312] This is a blinded, placebo-controlled study. The objectives of this study are: Pseudomonas aeruginosa The objective of the present invention is to evaluate the antibacterial activity of the claimed drug in experimental infection of rats with (RP73). This bacterium causes chronic pulmonary infection with irreversible lung damage in about 80% of adult patients. The drug of the present invention contains four technical preparations obtained by serial dilution of affinity purified monoclonal antibody stock material, namely: 1) antibodies against HLA-DRB1 (diluted in C10D40C150 (3mg / ml) in a ratio of 2:3:1), 2) antibodies against β2-microglobulin (diluted in C10C150 (3mg / ml) in a ratio of 3:1), 3) antibodies against interferon gamma (diluted in C10D40C150 (3mg / ml) in a ratio of 2:3:1), and 4) antibodies against CD4 (diluted in C10C30C200 (3mg / ml) in a ratio of 2:3:1) in a volume ratio of 1:1:1:1.
[0313] Experimental Group: Group 1- Pseudomonas aeruginosa Strain RP73 (intratracheal route, 6.5 * 10 7 Male Sprague-Dawley rats (n=10) infected with 1000 ng / ml of 1000 ng / mL IgG and not administered any drug (naive animals).
[0314] Group 2- Pseudomonas aeruginosa Strain RP73 (intratracheal route, 6.5 * 10 7 CFU / ml) 24 h before infection and 24, 48, 72, and 96 h after infection were orally administered placebo (purified water) to male Sprague-Dawley rats (n=10). Dose volume-7.5 ml / kg.
[0315] Group 3- Pseudomonas aeruginosa Strain RP73 (intratracheal route, 6.5 * 10 7 Male Sprague-Dawley rats (n=10) were administered the comparator drug tobramycin at a dose of 3 mg / kg via the oropharyngeal route 24 hours before infection and 24, 48, 72 and 96 hours after infection with 1000 CFU / ml. Dosage volume-7.5 ml / kg.
[0316] Group 4- Pseudomonas aeruginosa Strain RP73 (intratracheal route, 6.5 * 10 7 Male Sprague-Dawley rats (n=10) were orally administered the claimed drug 24 hours before infection and 24, 48, 72 and 96 hours after infection with 100 mg of 1000 CFU / ml. Dosage volume-7.5 ml / kg.
[0317] Test Design: The test period was 7 days. * 10 7 CFU / ml by intratracheal route Pseudomonas aeruginosa (RP73). Placebo (purified water) and the claimed test substance were administered orally at a dose of 7.5 ml / kg 24 hours before infection and 24, 48, 72, and 96 hours after bacterial inoculation. The comparator drug tobramycin was administered to the animals by the oropharyngeal route at a dose of 3 mg / kg at the same time points.
[0318] The body weight of the animals was measured throughout the study.
[0319] On day 5 post-infection, rats were sacrificed and bronchoalveolar lavage fluid and lung samples were collected for bacterial load analysis. Lungs were homogenized and all samples were serially diluted, then 40 μl of the resulting dilutions were plated in triplicate on modified Drygalski-Conradi medium for Gram-negative bacteria. After 24 hours, CFU numbers were counted in bronchoalveolar lavage fluid and lung preparations.
[0320] Statistical analysis of findings was performed using two-way repeated measures ANOVA combined with post-hoc Tukey's test. Differences were considered statistically significant when p<0.05.
[0321] Test results: It is the most common bacterium causing chronic lung infections associated with irreversible lung damage. Pseudomonas aeruginosaIntratracheal infection of rats with (RP73) led to a deterioration in the animals' general condition and associated weight loss. In group 1 (untreated animals), this parameter decreased by 27% by the end of the experiment compared to baseline. A similar effect was observed in group 2 (placebo), where it decreased by 28%.
[0322] The use of the claimed drug (group 4) promoted an improvement in the general health of the infected rats: weight loss was less pronounced compared to groups 1 and 2, with an overall reduction of 15%. The comparative drug exerted the greatest protective effect: group 3 (tobramycin) had only a 4% reduction in mean weight by the end of the study (Figure 25).
[0323] Pseudomonas aeruginosa Estimation of bacterial load in lung and bronchoalveolar lavage samples of rats 5 days after intratracheal infection with (RP73) showed that the claimed drug exerted a significant antibacterial effect when administered during the therapeutic and prophylactic course of treatment, i.e., 24 hours before infection and 24, 48, 72, and 96 hours after intratracheal inoculation of the bacteria. Unlike the placebo group (group 2), where the CFU counts did not show significant differences compared to group 1 (untreated animals), the claimed drug reduced the lung CFU counts by 29% compared to untreated animals and 19% compared to placebo (Figure 26), and the bronchoalveolar lavage fluid CFU counts by 33% and 34%, respectively (Figure 27). Pulmonary bacterial load values obtained with the comparative drugs were similar to those of the claimed drug. That is, the reduction in lung CFU in response to tobramycin was 29% compared to untreated animals and 19% compared to placebo. The antibacterial activity of tobramycin was found to be more pronounced in bronchoalveolar lavage fluid samples. That is, 88% compared with the two control groups (untreated animals and placebo).
[0324] Conclusion: A bacterium that causes chronic pulmonary infection with irreversible lung damage in approximately 80% of adult rats Pseudomonas aeruginosaIn tests carried out with experimental infection of rats with baculovirus (strain RP73), the claimed drug was shown to exert a significant antibacterial effect, as shown by less weight loss, an important indicator of the general health of the animals, and a reduction in the bacterial load in the lungs (1.2-1.4 times) and in bronchoalveolar lavage fluid samples (1.5 times).
[0325] Example 17 Porphyromonas gingivalis Efficacy of drugs in mice infected with (ATCC 33277)
[0326] This is a blinded, placebo-controlled study. The objectives of this study are: Porphyromonas gingivalis The aim of the study was to evaluate the antibacterial and immunotropic (anti-inflammatory) effects of the claimed drug in experimental infection of mice with erythropoietin (one of the main pathogens causing periodontal disease). The drug of the present invention contains technical preparations obtained by serial dilution of a stock material of affinity purified polyclonal antibodies, namely: 1) antibodies against HLA-DRB1 (diluted in C50C200 (1.5mg / ml) in a ratio of 2:3), 2) antibodies against β2-microglobulin (diluted in C50C200 (1.5mg / ml) in a ratio of 1:2), 3) antibodies against interferon gamma (diluted in C50C200 (1.5mg / ml) in a ratio of 1:3), and 4) antibodies against CD4 (diluted in C50C200 (1.5mg / ml) in a ratio of 3:2) in a volume ratio of 2:3:2:1.
[0327] Experimental Group: Group 1- Porphyromonas gingivalis ATCC 33277 (subcutaneous, 10 8 Male C57B6 / Ntac mice (n=10) infected with 1000 ng / mL IgG1 (CFU / animal) and received no drug (naive animals).
[0328] Group 2- Porphyromonas gingivalis ATCC 33277 (subcutaneous, 10 8Male C57B6 / Ntac mice (n=10) were orally administered placebo (purified water) at 2, 24, 48 and 78 hours after infection with 1000 ng / animal CFU. Dosing volume-10 ml / kg.
[0329] Group 3- Porphyromonas gingivalis ATCC 33277 (subcutaneous, 10 8 Male C57B6 / Ntac mice (n=10) were orally administered the claimed drug at 2, 24, 48 and 78 hours after infection with 100 μg / kg of 10 ...
[0330] Test Design: The test period was 25 days. Porphyromonas gingivalis (ATCC 33277), 10 8 Mice were challenged by subcutaneous injection into pre-implanted chambers at a dose of CFU / animal [Infect Immun. 1991 Apr;59(4):1255-63].
[0331] Test substances were administered orally at a volume of 10 ml / kg at 2, 24, 48 and 72 hours post-infection.
[0332] Four days after bacterial inoculation, the pre-implanted subcutaneous chambers were removed and the bacterial load and inflammatory cytokine levels (IL-1β, IL-6) in the chambers were measured.
[0333] To estimate the bacterial load, 20 μl of serially diluted chamber fluids were plated in triplicate on Brucella blood agar plates and incubated under anaerobic conditions for 96 h.
[0334] Cytokine levels were measured by ELISA using a test system from R&D Systems (USA) according to the manufacturer's instructions.
[0335] Statistical analysis of findings was performed using the Kruskal-Wallis test combined with post-hoc Tukey's test and Kaplan Meier curves, followed by pairwise comparisons with the log-rank test. Differences were considered statistically significant when p<0.05.
[0336] Test results: 10 in a subcutaneously implanted chamber 8 The bacterial load values obtained ( CFU / mouse) on day 4 after in vivo injection of bacteria Porphyromonas gingivalis The number of CFU, ATCC 33277, in the 100% control group (n=100) showed significant antibacterial activity of the claimed test substance when administered during the course of treatment, i.e., 2, 24, 48, and 72 hours after infection. Unlike the placebo group (group 2), where the CFU count was similar to group 1 (untreated animals), the claimed drug reduced the CFU count by 41% compared to untreated animals and by 34% compared to placebo (Figure 28).
[0337] 10 8 At a dose of CFU / mouse, Porphyromonas gingivalis The immunotropic activity of the claimed drug was found to be significant when assessed by measuring the effect of the claimed drug on cytokine levels (IL-1β and IL-6) in subcutaneously implanted chambers 4 days after in vivo injection of (ATCC 33277). A statistically significant reduction in cytokine levels was recorded in response to the claimed drug compared to controls and group 1 (untreated animals): IL-1β was reduced by 49% vs. group 1 and 41% vs. group 2 (placebo), and IL-6 was reduced by 60% vs. group 1 and 63% vs. group 2 (Figures 29, 30).
[0338] Conclusion: Therefore, it is one of the main pathogens causing periodontal disease. Porphyromonas gingivalisIn studies conducted using experimental infection of mice with B. difficile, the claimed drug was shown to exert significant antibacterial and immunotropic (anti-inflammatory) effects resulting in an approximately three-fold reduction in bacterial load and a reduction in pro-inflammatory cytokine levels (1.7-fold reduction in IL-1β and 2.7-fold reduction in IL-6) compared to placebo.
[0339] Example 18 Mycobacterium Tuberculosis Antibacterial activity of the claimed drug against H37Rv strain
[0340] This is a blinded, placebo-controlled study. The objectives of this study are: Mycobacterium Tuberculosis The object of the present invention is to evaluate the antibacterial activity of the claimed drug in experimental infection of mice with IgG (strain H37Rv). The drug of the present invention contains technical preparations obtained by serial dilution of affinity purified monoclonal antibody stock material, i.e. 1) antibodies against HLA-DRB1 (diluted at 2 mg / ml in C12C30C50 in a ratio of 3:2:1), 2) antibodies against β2-microglobulin (diluted at 2 mg / ml in C12C30C50 in a ratio of 3:2:1), 3) antibodies against interferon gamma (diluted at 2 mg / ml in C12C30C50 in a ratio of 3:2:1), and 4) antibodies against CD4 (diluted at 2 mg / ml in C12C30C50 in a ratio of 3:2:1) in a volume ratio of 2:2:2:1:2.
[0341] Group 1- Mycobacterium Tuberculosis H37Rv(5 * 10 4 Female C57BL / 6 mice (n=15) were infected intravenously with 1000 ng / animal (CFU / animal) and received no drug (naive animals).
[0342] Group 2- Mycobacterium Tuberculosis H37Rv (intravenous route, 5 * 10 4 Female C57B6 / Ntac mice (n=15) were orally administered placebo (purified water) for 4 weeks starting from day 22 post-infection with 1000 ng / animal (CFU / animal). Dose volume-10 ml / kg.
[0343] Group 3- Mycobacterium Tuberculosis H37Rv (intravenous injection, 5 * 10 4 CFU / animal) for 4 weeks starting on day 22 postinfection with female C57BL / 6 mice (n=15) orally administered a combination of comparator drugs, i.e., isoniazid (25 mg / kg) + rifampicin (20 mg / kg) + ethambutol (100 mg / kg).
[0344] Group 4- Mycobacterium Tuberculosis H37Rv (intravenous injection, 5 * 10 4 Female C57BL / 6 mice (n=15) were orally administered the claimed drug for 4 weeks starting from day 22 post infection with 1000 ng / animal (CFU / animal). Dosage volume-10 ml / kg.
[0345] Test Design: The test period was 50 days. Mycobacterium Tuberculosis For the H37Rv strain, 5 * 10 4 Mice were challenged by intravenous injection at a dose of 100 CFU / animal.
[0346] In groups 2 and 4, the test substances were administered orally at a dose of 10 ml / kg during the treatment course, i.e., for 28 days from day 22 after infection. In group 3, the comparison drug (a combination of isoniazid (25 mg / kg) + rifampicin (20 mg / kg) + ethambutol (100 mg / kg)) was administered according to the same regimen.
[0347] Until the end of the experiment, 50 days after infection, mice were sacrificed and their lungs were Mycobacterium Tuberculosis Isolated lungs were homogenized, serially diluted, and 20 μl of the dilutions were plated in triplicate on 7H11 agar plates and incubated for 24 hours.
[0348] Statistical analysis of findings was performed using two-way ANOVA combined with post-hoc Tukey's test. Differences were considered statistically significant when p<0.05.
[0349] Test results: Mycobacterium Tuberculosis Estimated lung bacterial burden in mice infected with (H37Rv) showed a reduction in CFU counts in response to the claimed drug compared to Group 1 (untreated animals) and Group 2 (placebo) (43% and 37% reduction, respectively). The comparator drug (Isoniazid (25 mg / kg) + Rifampicin (20 mg / kg) + Ethambutol (100 mg / kg) combination) exerted a similar effect by reducing bacterial burden by 54% and 49% compared to untreated animals and placebo groups, respectively (Figure 31).
[0350] Conclusion: therefore, Mycobacterium Tuberculosis Studies conducted using a mouse model of (H37Rv)-induced infection showed a significant antibacterial effect of the claimed drug, with a two-fold reduction in the bacterial burden in the lungs.
[0351] Example 19 Salmonella Typhimurium Evaluation of potential mutagenic activity of claimed drugs by mutagenicity testing
[0352] The purpose of this study is to: Salmonella TyphimuriumThe object is to investigate the potential mutagenicity of the claimed drug in a mutagenicity test (Ames test).The drug 1 of the present invention contains a technical preparation obtained by serial dilution of a stock material of an antibody against HLA-DRB1 (aqueous dilution of polyclonal antibody in a ratio of 1:1:1, 2.5 mg / ml) and a technical preparation obtained by serial dilution of a stock material of a releasing active antibody against β2-MG (aqueous dilution of polyclonal antibody in a ratio of 1:1:1, 2.5 mg / ml) in a volume ratio of 1:1. Medicament 2 of the present invention contains a) an antibody against HLA-DRB1 (dilution of polyclonal antibody in C12C30C50 in a ratio of 1:1:1, 2.5 mg / ml), b) an antibody against β2-microglobulin (dilution of polyclonal antibody in C12C30C50 in a ratio of 1:1:1, 2.5 mg / ml), c) an antibody against interferon gamma (dilution of polyclonal antibody in C12C30C50 in a ratio of 1:1:1, 2.5 mg / ml), and d) an antibody against CD4 (dilution of polyclonal antibody in C12C30C50 in a ratio of 1:1:1, 2.5 mg / ml) in a volume ratio of 1:1:1:1.
[0353] Test Design: The Ames test is performed with and without metabolic activation. Salmonella Typhimurium Tester strains TA97a, TA98, TA100, TA102, and TA1535 were employed. When tested in the presence of a metabolic activation system, biotransformation of the test substances was achieved using a mixture of S9 fractions containing microsomal metabolic enzymes prepared by centrifugation (9000 g) of liver homogenates obtained from outbred white rats. Enzyme induction was performed with sovol administered to rats by intraperitoneal route at a dose of 300 mg / kg.
[0354] Test drugs and purified water (control) were tested at a dilution factor of 10 within the assay standard dose range of 0.1-1000 μl / plate. The direct mutagenic activity of the claimed drugs was evaluated in assays without metabolic activation. In these assays, 100 μl of drug and 100 μl of bacterial culture were poured onto the plates, and no microsomal mixture was added to the samples. Positive controls were prepared with standard mutagens, i.e., sodium azide (at a concentration of 5 μg per plate) for strain TA100, 9-aminoacridine (10 μg / plate) for strain TA97, and 2,7-diamino-4,9-dioxy-5,10-dioxo-4,5,9,10-tetrahydro-4,9-diazopyrene (DDDTDP; 100 μg / plate) for strain TA98. In assays without metabolic activation, the promutagen cyclophosphane was used (500 μg / plate). Bacteria and test substances were inoculated onto minimal medium plates and incubated at 37° C. for 2 days, after which the number of histidine revertant colonies was counted. Each concentration was tested on three plates.
[0355] For each experimental model, the geometric mean number of revertant colonies per three plates was determined. The standard deviation was calculated as the maximum deviation of the revertant count on one of the three plates from the geometric mean count. The significance of the increase in the geometric mean revertant count in the assay with the test composition relative to the control value was evaluated using a modified multiple comparison test (Dunnett's test). Differences were considered statistically significant when p<0.05.
[0356] Test results: The number of revertants was similar to that of the controls under the test conditions applied to the claimed drug.
[0357] Conclusion: Since sovol, which enhances the activity of various classes of cytochrome P450-dependent monooxygenases, was used as a biotransformation enzyme inducer to achieve metabolic activation of the claimed drug, it can be concluded that the possible metabolites of the drug of the present invention do not have mutagenic activity. Therefore, the claimed drug is considered to be non-mutagenic.
[0358] Example 20 Toxicity testing of patented medicines
[0359] Toxicity studies were performed in accordance with Good Laboratory Practice (GOST 33044-2014) and the guidelines on non-clinical studies of pharmaceutical products [Mironov AN, Bunatyan ND. Guidelines on non-clinical studies of pharmaceutical products. Moscow, Grif and Co. 2012; 944 p.].
[0360] Since the general pharmacokinetic and pharmacodynamic models (dose-concentration-effect relationships) approved for the majority of pharmaceuticals cannot be applied to the claimed drugs (technical products obtained from serial dilutions of stock substances of the respective antibodies against HLA-DRB1 and β2-MG) (available physicochemical and immunological methods are not capable of detecting drug concentrations in biological fluids of living organisms), dose selection for toxicity testing is based on a physiologically acceptable amount of the solvent (purified water in experimental tests) to which the drug is added.
[0361] Acute toxicity: The study was performed using intragastric administration in male and female adult outbred albino mice (body weight 22-26g, age 2.5 months) and male and female adult Wistar rats (body weight 225-250g, age 4 months). Two doses of either the test drug (n=18) or purified water (control, n=18) were administered intragastrically at 2-hour intervals, with a maximum dose of 25ml / kg in mice and 20ml / kg in rats. The intact group did not receive the compound (n=18). The follow-up period after administration was 2 weeks.
[0362] Statistical analysis of the data obtained was performed using two-way ANOVA followed by post-hoc Tukey's test for between-group comparisons. Differences were considered statistically significant when p<0.05.
[0363] Administration of the claimed drug, comprising a technical preparation obtained from multiple serial dilutions of a stock material of antibodies against HLA-DRB1 (aqueous dilution of polyclonal antibodies in the ratio 2:1:3 in C12C30C50, 2.5 mg / ml) and a technical preparation obtained from multiple serial dilutions of a stock material of antibodies against β2-MG (aqueous dilution of polyclonal antibodies in the ratio 2:1:3 in C12C30C50, 2.5 mg / ml) by intragastric route in the maximum dose to adult mice and rats, did not affect the general health of the animals (no signs of anxiety, appetite, excretion, changes in mucus membrane, hair, skin, etc.) or the weight gain of rats and mice (both male and female).
[0364] Similar results were obtained under the same conditions as above using the pharmaceutical of the present invention, which contains technical preparations obtained from serial dilutions of stock materials of a) antibodies against HLA-DRB1 (polyclonal C12C30C50 dilution in a ratio of 1:3:1, 2.5mg / ml), b) antibodies against β2-MG (polyclonal C12C30C50 dilution in a ratio of 1:3:1, 2.5mg / ml), c) antibodies against IFN-γ (polyclonal C12C30C50 dilution in a ratio of 1:3:1, 2.5mg / ml) and d) antibodies against CD4 (polyclonal C12C30C50 dilution in a ratio of 1:3:1, 2.5mg / ml).
[0365] Since no animals administered the drug died, it was not possible to calculate an LD50, and therefore doses exceeding the maximum dose of the drug were taken as the conventional LD50.
[0366] Since two intragastric doses of the claimed drug at the maximum dose were not found to cause any toxic effect on the health of animals, it is concluded that the claimed drug is safe and can be classified as of low toxicity and can be assigned to category 5 in accordance with the GHS classification.
[0367] Repeated Dose Toxicity: The study was conducted on 200 adult male and female conventional albino rats (weight 180-242 g, age 3.5-4 months) and 24 adult male and female chinchilla rabbits (weight 1.9 kg, age 2.5-3 months). Since it was not possible to determine the LD50 value of the drug, in this chronic toxicity study, the drug or purified water was administered intragastrically to rats at the maximum dose tolerated for intragastric administration and at 25% of the maximum dose. The drug was administered to rabbits in an amount approximating their daily water intake.
[0368] The treatment period was 6 months, and the health status of the rats and rabbits was evaluated 3 and 6 months after the start of drug treatment, and 1 month after discontinuation.
[0369] Long-term intragastric administration of the drug of the present invention to adult male and female rats at doses more than 100 times the maximum daily dose in humans did not result in any animal deaths during the 6-month administration period, nor did it cause any significant changes in the animals' behavior or the morphological and functional parameters of peripheral blood compared to the control group 3 and 6 months after administration of the drug and 1 month after discontinuation of administration of the drug.
[0370] Moreover, chronic administration of the drug at said doses was not accompanied by significant changes in the macro- and micro-morphological and histological structure of the rat internal organs.
[0371] In the rabbit study, no deaths were observed throughout the study period. Long-term administration of the drug had no significant effect on the general health, behavior, and body weight of the animals, or on the hematopoietic parameters of peripheral blood and bone marrow. The biochemistry of rabbit plasma showed no significant changes. Furthermore, no changes were observed in the urine of rabbits administered the drug for 6 months. Macroscopic examination of the internal organs of rabbits administered the drug for 6 months showed no abnormal changes. Histological examination of organ tissues showed no abnormalities.
[0372] Conclusion: Based on the tests carried out, it can be concluded that the claimed drug, when administered intragastrically to adult rats at a dose of 10 ml / kg and to rabbits at a dose of 50 ml / kg (more than 100 times the average daily dose in humans) for a period of 6 months, does not significantly affect the animals' general health and behavior and does not cause any abnormalities or morphofunctional changes in the cardiovascular, gastrointestinal and excretory systems.
[0373] Example 21 A multicenter, double-blind, placebo-controlled, randomized clinical trial of the claimed drug in the treatment of acute respiratory viral infections.
[0374] The aim of this study was to evaluate the efficacy and safety of the claimed drug in the treatment of acute respiratory viral infections (ARVI).The preparation according to the invention in the form of a tablet for absorption contains identical amounts of four technical preparations obtained from serial dilutions (dilutions C12C30C50) of affinity purified polyclonal stock materials of a) antibodies against HLA-DRB1, b) antibodies against β2-microglobulin, c) antibodies against interferon gamma and d) antibodies against CD4 applied in the form of a water-alcohol mixture to lactose monohydrate.
[0375] Test Design: The study included male and female outpatients (240 patients) aged 18-70 years who showed clinical symptoms of ARVI (axillary temperature ≥ 38.0°C at examination + total severity of general symptoms ≥ 4 points, nose / throat / chest symptoms ≥ 2 points) on day 1 of illness onset. Patient recruitment was carried out during the seasonal outbreak period of ARVI.
[0376] After undergoing screening procedures, 240 patients were randomized into two groups: 118 in the drug group (taking the claimed drug according to the regimen for 5 days) and 122 in the placebo group (taking placebo according to the regimen for 5 days). The results of treatment and observation of these patients (n=240) were used to evaluate the safety and efficacy of the target treatment among ARVI patients and were confirmed by PCR (n=78 in the drug group and n=73 in the placebo group). Data from 6 patients (3 patients in the drug group and 3 patients in the placebo group) were not included in the PP (protocol set) analysis of efficacy due to protocol deviations (prescription of prohibited therapeutic drugs). The number of patients who received the full treatment, completed all prescribed interventions, and did not have any significant deviations from the protocol was 234, including 115 in the drug group and 119 in the placebo group. The data of these patients were used for RR analysis of drug efficacy among ARVI patients etc. and confirmed by PCR (n=76 in the drug group and n=72 in the placebo group).
[0377] Patients were followed up for 14 days (screening, randomization - maximum 1 day; treatment - 5 days; follow-up - maximum 2 days; delayed telephone "visit" - 14 days). During the course of treatment and follow-up, patients visited their primary care physician / physician three times and had an additional fourth telephone "visit". During visits 2 and 3, the attending physician performed objective examinations, recorded the dynamics of disease symptoms, concomitant medications, and administered the completion of a diary. At visit 3, compliance was assessed and laboratory tests were performed. The study also used an electronic patient diary (EPD), where axillary temperature and disease symptoms were recorded daily, in the morning and in the afternoon.
[0378] Treatment design: Dosage scheme of the claimed drug: 1 tablet per dose. Day 1 of treatment: 1 tablet every 30 minutes for the first 2 hours, then 3 more times periodically on day 1. Days 2-5: 1 tablet 3 times a day. The drug is taken outside of meals (between meals or 15-30 minutes before meals) and the tablet is kept in the mouth without being swallowed until it is completely dissolved. The duration of hospitalization is 5 days.
[0379] Comparison treatment: placebo lozenges according to the claimed drug regimen for 5 days.
[0380] Basic and concomitant therapy: During the study, patients were allowed to receive medicines for the symptomatic treatment of ARVI (antipyretics / nonsteroidal anti-inflammatory drugs (paracetamol / ibuprofen) and / or nasal vasoconstrictors - oxymetazoline / naphazoline and / or antitussives / expectorants - butamirate / ambomyrate, guaifenesin, acetylcysteine).
[0381] sample: Total Set - These are all patients enrolled in the study who have signed the Patient Information Sheet and Informed Consent Form. This sample includes all adverse events (AEs) recorded during the study, including before the start of study treatment.
[0382] Safety Analysis Population - All randomized patients who received at least one dose of study drug. This sample was used for the analysis of study drug safety as it recorded all AEs identified in patients after drug administration. AEs reported in patients in the total set sample after the time informed consent was signed but before taking study drug will not be considered in the study drug safety analysis.
[0383] Full Analysis Set (ITT Population). These are all patients who were included and randomized, except for those who experienced at least one of the following events: 1) non-compliance with inclusion / exclusion criteria; 2) the patient did not take any study medication; 3) Loss of patient data after randomization and study drug administration.
[0384] This sample, which is most consistent with the "intention-to-treat" principle, was used for intention-to-treat analysis of the efficacy of the study therapy (ITT analysis).
[0385] To fill in missing / missing data (indicators / options), we used the last observation carried forward (LOCF) method.
[0386] Per-protocol population. This sample included all patients who received the full treatment prescribed by the protocol, completed all scheduled visits, and had no significant deviations from the protocol. This sample was used for the per-protocol population analysis of the efficacy of the study treatment (PP analysis).
[0387] The per-protocol population sample did not include patients whose data were completely or partially unsuitable for analysis as a result of identified protocol deviations.
[0388] Statistical methods: To compare the results of the two groups for continuous variables, the two-sample Student's t-test or the nonparametric Wilcoxon test was used depending on the results of the Shapiro-Wilk test for normality. Analysis of variance (Mixed procedure of SAS) was used to compare the changes of indicators in the two groups. The Kruskal-Wallis test was used to analyze the vital signs of the patients. To compare the proportions (percentages) in the two groups, Fisher's exact test or the Cochran-Mantel-Hensel test was used, with the applicability of the latter tested by the Breslow-Day test.
[0389] Effect assignment: Analysis of treatment effectiveness by primary endpoint Time to disappearance of ARVI symptoms (confirmed by PCR). Against the background of treatment with MMN-407, the time to disappearance of all symptoms of the disease in patients with ARVI confirmed by PCR (with virus detected in nasopharyngeal samples) was 4.1 ± 1.9 [4.0 ± 1.9] days (versus 5.0 ± 2.5 [5.0 ± 2.5] days on the background of placebo therapy) (Table 7). Table 7. Time to resolution of ARVI symptoms (confirmed by PCR). [Table 7]
[0390] In the drug group, disease lasted less than 3.0 [2.8] days in 25% of patients and between 3.0 [2.8] and 5.0 [5.0] days (the border between the lower and upper quartiles) in 50%. In the placebo group, 25% of patients had symptoms of disease for 6.0 [6.3] days or more (upper limit of the upper quartile).
[0391] Among patients in the drug group included in the ITT analysis, the duration of ARVI disease was on average -0.89 ± 2.23 days shorter than in the placebo group (delta between the two groups). In patients in the drug group who completed treatment and observation according to the protocol, the duration of ARVI was approximately 1 day shorter ([-0.93 ± 2.25], data obtained by RR analysis).
[0392] Analysis of treatment efficacy with further endpoints
[0393] 1) The proportion of patients whose ARVI symptoms (clinically diagnosed and / or PCR-confirmed) disappeared The percentage of patients with resolved ARVI symptoms (clinically diagnosed, including those confirmed by PCR) gradually increased from the third day of treatment. On the fifth day of treatment, more than half of the patients (62.7 [64.4]%) in the drug group were healthy (Figure 32). At the end of the fifth day of treatment, 72.9 [73.0]% of patients administered the claimed drug had recovered from ARVI.
[0394] Statistical analysis showed that the proportion of patients who completed study participation according to the protocol and recovered was higher in the drug group than in the placebo group throughout the treatment period (Cochran-Mantel-Hensel test; data obtained by RR analysis: [p=0.0201]).
[0395] 2) Time to disappearance of ARVI symptoms (clinical diagnosis including PCR confirmation)
[0396] Analysis of data on a further endpoint estimating the time to disappearance of ARVI symptoms (clinically diagnosed, including PCR confirmation among all randomized participants) also shows the benefit of using the medicine in addition to symptomatic ARVI therapy (Table 8). Table 8. Time to resolution of ARVI symptoms (clinical diagnosis including PCR confirmation). [Table 8]
[0397] In the drug group, disease lasted less than 3.0 days in 25% of patients and 50% between 3.0 and 5.5 days (the border between the lower and upper quartiles). In the placebo group, 25% of patients had disease symptoms for more than 6.0 days (the upper limit of the upper quartile).
[0398] Among patients in the drug group included in the ITT analysis, the duration of clinically diagnosed ARVI disease, including PCR confirmation, was on average -0.41 ± 2.34 days shorter than in the placebo group (delta between the two groups). In patients in the drug group who completed treatment and observation according to the protocol, the duration of ARVI was [-0.47 ± 2.36] days shorter (data obtained by RR analysis).
[0399] Thus, in all patients with clinically diagnosed ARVI, including those confirmed by PCR, the time to resolution of symptoms was shorter in the drug group than in the placebo group.
[0400] 3) The number of times to take antipyretics according to symptoms during the 1-3 day treatment period
[0401] Antipyretics (paracetamol or ibuprofen dispensed by the investigator at visit 1) were permitted during the study according to medical indications.
[0402] Antipyretics were prescribed a mean of 0.30 ± 0.68 [0.28 ± 0.67], 0.19 ± 0.48 [0.20 ± 0.48], and 0.03 ± 0.22 [0.02 ± 0.13] times in the drug group and 0.38 ± 0.67 [0.36 ± 0.64], 0.24 ± 0.53 [0.23 ± 0.53], and 0.04 ± 0.20 [0.04 ± 0.20] times in the placebo group on the 1st, 2nd, and 3rd days of illness.
[0403] Statistical analysis showed no between-group differences in the number of antipyretics taken within 1 to 3 days of observation.
[0404] Thus, the effectiveness of the claimed drug in the treatment of patients with ARVI is shown when there is no difference in the use of symptomatic medicines, including antipyretics.
[0405] The proportion of patients who showed a worsening of the disease course (development of complications requiring antibiotics or hospitalization) within 4 to 14 days of observation
[0406] In the drug group (N=118), of all randomized patients with ARVI (clinically diagnosed, including PCR-confirmed), one patient (0.8%) for whom an antibiotic was prescribed was diagnosed as acute bronchitis. In the placebo group (N=122), three patients (2.5%) were prescribed antibiotics for bacterial complications, including pneumonia (hospitalized patient, n=1), acute purulent bronchitis (n=1), and sinusitis (n=1).
[0407] Thus, the inclusion of the claimed drug in the ARVI complex treatment helped to prevent the worsening of the course of the disease and the development of bacterial complications requiring antibacterial therapy and hospitalization of the patient.
[0408] Safety rating: Safety assessment and treatment tolerability were based on data obtained from all included and randomized patients who received at least one dose of study drug / placebo (safety analysis set; n=240). Vital signs of study participants were assessed and adverse events (AEs), their relationship to medication, severity, and outcome were recorded. Dynamics of laboratory parameters (clinical blood analysis, routine urine analysis, biochemical markers) were investigated.
[0409] 1) Dynamics of vital signs.
[0410] The claimed drug did not adversely affect the important functions of the study participants, such as systolic (SBP), diastolic (DBP) blood pressure, heart rate (HR), and respiratory rate (RR).
[0411] Mean SBP and DBP values throughout the study corresponded to normal and well-controlled values.Statistical analysis showed no differences in SBP, DBP, heart rate, and RR between treatments 1-3 in the drug and placebo groups.
[0412] 2) Adverse events In total, 9 AEs were recorded in 9 (7.6%) patients in the drug group and 11 AEs were recorded in 9 (7.4%) participants in the placebo group during the treatment and follow-up period. Among all AEs, the most common were upper abdominal pain (n=2, drug group; n=0, placebo group), infections and infiltrates (including community-acquired pneumonia, n=1, placebo group; sinusitis, n=1, placebo group); acute bronchitis, n=1, drug group and n=1, placebo group; acute nasopharyngitis, n=1, drug group; acute tubo otitis, n=1, drug group; herpes simplex, n=1, drug group and n=1, placebo group), and general disorders and reactions at the injection site (n=2, placebo group; in the form of lip edema, n=1, disease exacerbation, n=1).
[0413] In the drug group, 9 (100.0%) AEs were mild; in the placebo group, 11 (100.0%). According to the investigators, there was no causal relationship between the AEs and the claimed drug under study.
[0414] 3) Dynamics of laboratory parameters To assess the safety of the treatment, blood and urine biochemical and general clinical parameters were examined. Both at baseline and at the end of the treatment course, the mean values of these laboratory parameters did not exceed the reference values corresponding to normal indicators for the given age and sex.
[0415] Thus, the analysis of safety parameters showed that the drug is safe in the treatment of patients with ARVI.
[0416] Conclusion: This study shows that a 5-day treatment with the claimed drug is effective and safe for ARVI patients. The use of the drug according to the invention leads to a faster disappearance (recovery) of ARVI symptoms, which indicates the advantage of including the drug in ARVI combination therapy. [Prior art documents] [Patent documents]
[0417] [Patent Document 1] Russian Patent No. 2363470C1 (October 8, 2009) [Patent Document 2] Russian Patent No. 2655808C2 (May 29, 2018) [Patent Document 3] Russian Patent No. 2205025C1 (December 26, 2001) [Patent Document 4] Russian Patent No. 2521392 (August 6, 2010) [Non-patent literature]
[0418] [Non-Patent Document 1] WHO. The evolving threat of antimicrobial resistance: Options for action. 2013 [Non-Patent Document 2] Leneva I.A. et al. Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol. Antiviral Res 2009 81(2):132-40 [Non-Patent Document 3] Belozertseva V.N. et al. Antibiotics: resistance and toxicity. New St. Petersburg Medical Records, 2017.-N 2. -P.59-61
Claims
1. A medicament for the treatment of a bacterial infection, comprising: A technical process resulting from multiple serial dilutions of stock material of antibodies against the β1 domain of major histocompatibility complex class II molecules (HLA-DRB1) and antibodies against β2-microglobulin (β2-MG), The concentration of the stock material is 0.5÷5.0 mg / ml; A pharmaceutical preparation, characterized in that said technical products are aqueous or hydroalcoholic solutions obtained from serial dilutions of said stock material, each dilution being carried out with repeated shaking.
2. The bacterial infection is (i) an infection caused by a bacteria that is resistant to one or more known antibiotics; (ii) any urinary tract infection selected from cystitis and prostatitis; (iii) bacterial intestinal infection; (iv) bacterial skin infections; (v) tuberculosis, or (vi) any infection selected from salmonellosis, E. coli infection, streptococcal infection, and infection caused by Klebsiella pneumoniae The pharmaceutical composition according to claim 1,
3. The pharmaceutical according to claim 1, wherein the antibody is a monoclonal, polyclonal, or natural antibody against HLA-DRB1.
4. The pharmaceutical according to claim 1 , wherein the antibody is a monoclonal, polyclonal, or natural antibody against β2-microglobulin.
5. The pharmaceutical composition of claim 1 further comprising a pharma- ceutically acceptable additive.
6. The pharmaceutical of claim 1, prepared as a solid dosage form comprising an effective amount of neutral carrier granules impregnated with technical products resulting from multiple serial dilutions of stock materials of antibodies against HLA-DRB1 and antibodies against β2-microglobulin, and pharma- ceutical acceptable excipients.
7. A combination of a medicament for the treatment of a bacterial infection according to any one of claims 1 to 4 with an antibiotic, for simultaneous or sequential administration, The bacterial infection is (i) an infection caused by a bacteria that is resistant to one or more known antibiotics; (ii) any urinary tract infection selected from cystitis and prostatitis; (iii) bacterial intestinal infection; (iv) bacterial skin infections; (v) tuberculosis, or (vi) any infection selected from salmonellosis, E. coli infection, streptococcal infection, and infection caused by Klebsiella pneumoniae 2. A combination of a medicament and an antibiotic, comprising:
8. 8. The pharmaceutical-antibiotic combination of claim 7, wherein the antibiotic is selected from the penicillin class, the aminoglycoside class, the macrolide class, and the oxazolidinone class.
9. 8. Use of a combination of a medicament according to claim 7 with an antibiotic to reduce bacterial resistance to antibiotic therapy.
10. 10. The use of a pharmaceutical and antibiotic combination according to claim 9, wherein the antibiotic is present in a known effective dose.
11. 8. Use of a combination of the medicament according to claim 7 with an antibiotic to improve the efficacy of the antibiotic.
12. The antibiotic is administered at a 50% effective dose (ED 50 10. Use of a combination of the medicament according to claim 9 with an antibiotic, comprising
13. A medicament for treating an infectious disease, comprising: Technical products resulting from multiple serial dilutions of stock material of: a) antibodies against the β1 domain of major histocompatibility complex class II molecules (HLA-DRB1); b) antibodies against β2-microglobulin (β2-MG); c) antibodies against interferon gamma (IFN-γ); and d) antibodies against CD4, The concentration of the stock material is 0.5÷5.0 mg / ml; A pharmaceutical preparation, characterized in that said technical products are aqueous or hydroalcoholic solutions obtained from serial dilutions of said stock material, each dilution being carried out with repeated shaking.
14. The pharmaceutical composition according to claim 13, wherein the infectious disease is a viral infection or a bacterial infection.
15. The pharmaceutical composition of claim 14, wherein the viral infection is URI or influenza.
16. The method of claim 13, wherein the infection is a mixed infection.
17. The method of claim 13, wherein the infection is a secondary infection.
18. The method of claim 17, wherein the secondary infection is viral or bacterial pneumonia.
19. The pharmaceutical according to claim 13, wherein the antibody is a monoclonal, polyclonal, or natural antibody against HLA-DRB1.
20. The pharmaceutical according to claim 13, wherein the antibody is a monoclonal, polyclonal, or natural antibody against β2-microglobulin.
21. The method of claim 13, wherein the antibody is a monoclonal, polyclonal, or natural antibody against interferon gamma.
22. The pharmaceutical of claim 13 , wherein the antibody is a monoclonal, polyclonal, or natural antibody against CD4.
23. The pharmaceutical composition of claim 13, further comprising a pharma- ceutically acceptable additive.
24. The pharmaceutical of claim 13, formulated as a solid dosage form comprising an effective amount of neutral carrier granules impregnated with technical products resulting from multiple serial dilutions of stock materials of antibodies against HLA-DRB1, antibodies against β2-MG, antibodies against IFN-γ, and antibodies against CD4, and pharma- ceutical acceptable excipients.
Citation Information
Patent Citations
Combination pharmaceutical compositions and methods for treating functional disorders or conditions of the gastrointestinal tract.
JP2013532181A
Pharmaceutical composition and therapeutic method
JP2013535436A
Combination pharmaceutical compositions and methods for treating and preventing infectious diseases
JP2013537532A
Medicinal agent and method of treatment of erosive and inflammatory diseases of gastroenteric tract
RU2197266C1
Method of correction of immune response and medicinal agent
RU2205025C1
